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Abstract 
Bempedoic acid (BA) is a novel LDL cholesterol-lowering compound. Preclinical studies 
revealed that BA inhibits hepatic cholesterol and fatty acid synthesis through inhibition of 
ATP-citrate lyase and activation of AMP-kinase.  In the current study we tested the ability of 
BA to prevent diet-induced metabolic dysregulation, inflammation and atherosclerosis in 
Ldlr-/- mice fed a high-fat high-cholesterol diet (HFHC). BA supplementation to the HFHC 
diet at 3, 10 or 30 mg/kg/d significantly attenuated diet-induced hypercholesterolemia, 
hypertriglyceridemia, hyperglycemia, hyperinsulinemia, fatty liver and obesity over the 12-
week study compared to HFHC alone. Livers of BA-treated mice displayed decreased fatty 
acid synthesis, and increased β-oxidation, AMP-kinase activation, and peroxisome 
proliferation. BA reduced hepatic and aortic inflammatory gene expression and MAPK 
signaling, aortic esterified cholesteryl, and atherosclerotic lesion development. This 
demonstrates that BA effectively improves hepatic lipid metabolism and reduces plasma and 
tissue lipids, markers of inflammation, and atherosclerosis in a mouse model of metabolic 
dysregulation.  
Keywords 
LDL, cholesterol, dyslipidemia, atherosclerosis, inflammation, metabolic syndrome, 
NAFLD, Bempedoic Acid 
 iii 
 
Co-Authorship Statement 
The co-author contributions of this thesis are described below. 
Expertise and input for the conceptualization, design, and protocols of this study were 
provided by Dr. Murray W. Huff, Dr. Roger S. Newton, Dr. Sergey Filippov, and Stephen L. 
Pinkosky. Dr. Murray Huff also edited this thesis. Dr. J. Geoffrey Pickering provided access 
to the Molecular Pathology core facility at Robarts for histological analysis. Dr. Robert Gros 
provided access to the Comprehensive Lab Animal Monitoring System for metabolic cage 
experiments. Dr. Robert A. Hegele provided access to the London Regional Genomic Centre 
for gene expression analysis and the AKTA purifier and Superose 6 column for FPLC 
analysis. Dr. Maria Drangova and Dr. David W Holdsworth provided access to the Lotus 
Ultra micro-CT scanner for body composition analysis. Brian G. Sutherland, Dawn E. 
Telford, Jane Y. Edwards, Amy C. Burke, Julia M. St. John, and Andrew Q. Phu assisted 
with mouse husbandry, metabolic experiments and tissue harvesting. Brian G. Sutherland 
also assisted with lipid analysis and histological processing of tissues. Jane Y. Edwards also 
assisted with aortic gene expression analysis. Cindy G. Sawyez assisted with plasma lipid 
and ELISA analyses. Dr. Hao Yin, Dr. Zengxuan Nong, and Caroline O’Neil assisted with 
histological staining and quantitative analysis of tissues. Dr. Joseph Umoh, Dr. Maria 
Drangova, Joy Dunmore-Buyze, and Brian G. Sutherland performed micro-CT scanning. Dr. 
Joseph Umoh also performed processing and quantitative analyses of micro-CT scans. 
 
 
 iv 
 
Acknowledgments 
There are several individuals I wish to acknowledge for what I have been able to learn from 
them and for making this project a much more rewarding endeavor. 
First, I would like to thank my supervisor, Dr. Murray Huff, for providing me with the 
opportunity to carry out this work. His investment of time and resources into me made the 
success of this project possible and were key in my own learning and development as a 
researcher. I would also like to thank the members of my advisory committee, Dr. Geoffrey 
Pickering and Dr. Robert Gros, for their guidance and feedback. Thank you to all the 
members of the Huff Lab who contributed to this project: Brian Sutherland, Cindy Sawyez, 
Dawn Telford, Jane Edwards, Amy Burke, Andrew Phu, and Julia St. John. Although not 
involved with this project, I would also like to thank Kyle Seigel, also from the Huff Lab. It 
was a pleasure have the opportunity to mentor an undergraduate student. I enjoyed getting to 
work on the flavonoid study together, it’s a shame we couldn’t see it through to completion. 
To the many members of the fourth floor Vascular Biology group, I am hugely grateful for 
opportunities I had to meet and interact with you all. This includes the Gros, Hegele, and 
Pickering Labs whose collegiality and innovative spirits has been a pleasure to witness. I 
would especially like to thank Dr. Hao Yin, Sali Farhan, and John Robinson whose 
enthusiasm and willingness to exchange ideas were very encouraging to see. To Sharon 
Leung, Sina Ghoreishi, John-Michael Arpino, and Mouhamed Dakroub thank you for the 
enjoyable discussions. 
Another group worthy of very special acknowledgement is the lab of Dr. Khosrow Adeli, 
without whom I can certainly say I would not be where I am today. During my brief time 
working there I had the privilege of being mentored by Dr. Mark Dekker, while also working 
alongside Chris Baker, Mark Naples, Rianna Zhang, Wei Qui, Sara Farr, and Marsel Lino.  
This project would not be possible without having been wholly funded by Esperion 
Therapeutics Inc. Thank you to the founder of Esperion, Dr. Roger Newton, along with 
Stephen Pinkosky, Dr. Sergey Filipov, and Dr. Narendra Lalwani. Getting to witness drug 
discovery from an industry perspective was truly enriching to my graduate studies. I am 
 v 
 
excited to watch bempedoic acid continue through clinical development and am honored that 
I was able to play a part (however small) in this endeavor. 
I wish to express my sincere gratitude to my family and friends who supported me over the 
past few years. Most notably I wish to thank my Mom and Dad for their unending love and 
support.  
Above all, I thank God.  
Soli Deo Gloria, glory to God alone. 
 
 vi 
 
Table of Contents 
Abstract ............................................................................................................................... ii 
Co-Authorship Statement................................................................................................... iii 
Acknowledgments.............................................................................................................. iv 
Table of Contents ............................................................................................................... vi 
List of Tables ...................................................................................................................... x 
List of Figures .................................................................................................................... xi 
List of Abbreviations ....................................................................................................... xiii 
Chapter 1 ............................................................................................................................. 1 
1 Review of thesis topics................................................................................................... 1 
1.1 General Introduction ............................................................................................... 1 
1.2 Cardiovascular Disease and Dyslipidemia.............................................................. 1 
1.2.1 Atherogenesis .............................................................................................. 3 
1.2.2 Lipoproteins ................................................................................................ 8 
1.3 Lipoprotein Metabolism........................................................................................ 10 
1.3.1 Enteric lipoprotein production from exogenous lipids ............................. 10 
1.3.2 Hepatic lipoprotein production ................................................................. 10 
1.3.3 Metabolism of circulating lipoproteins ..................................................... 11 
1.4 Hepatic Fatty Acid and Cholesterol Metabolism .................................................. 12 
1.4.1 Cholesterol synthesis ................................................................................ 12 
1.4.2 Fatty acid synthesis ................................................................................... 12 
1.4.3 Sterol response element-binding proteins ................................................. 13 
1.4.4 Fatty acid oxidation................................................................................... 13 
1.5 Hepatic Insulin Signaling ...................................................................................... 14 
1.5.1 Regulation of glucose metabolism ............................................................ 15 
 vii 
 
1.5.2 Regulation of lipid metabolism ................................................................. 18 
1.5.3 Insulin resistance and Type 2 Diabetes ..................................................... 18 
1.6 Hepatic Steatosis and Inflammation ..................................................................... 19 
1.6.1 Normal liver biology and morphology ..................................................... 19 
1.6.2 Non-alcoholic fatty liver disease .............................................................. 24 
1.6.3 Non-alcoholic steatohepatitis and inflammation ...................................... 25 
1.6.3.1 Lipotoxicity ................................................................................ 25 
1.6.3.2 ER stress ..................................................................................... 25 
1.6.3.3 Reactive Oxygen Species ........................................................... 26 
1.6.3.4 Immune responses ...................................................................... 26 
1.6.4 Inflammatory signaling pathways ............................................................. 27 
1.6.4.1 MAPK pathways ........................................................................ 27 
1.6.4.2 NF-κB pathway .......................................................................... 28 
1.7 Modulating Lipoprotein Metabolism - Current and Potential Drug Targets ........ 32 
1.7.1 HMG-CoA reductase ................................................................................ 32 
1.7.2 Proprotein convertase subtilisin/kexin-9................................................... 32 
1.7.3 Niemann-Pick C1-like protein 1 ............................................................... 33 
1.7.4 Cholesterol ester transfer protein .............................................................. 33 
1.7.5 AMP-activated protein kinase................................................................... 34 
1.7.6 ATP-citrate lyase ...................................................................................... 38 
1.7.6.1 Bempedoic acid .......................................................................... 42 
1.8 Model to be used ................................................................................................... 45 
1.9 Hypothesis and Scope of Thesis ........................................................................... 45 
Chapter 2 ........................................................................................................................... 47 
2 Methods ........................................................................................................................ 47 
2.1 Animals and diets .................................................................................................. 47 
 viii 
 
2.2 Blood and tissue collection ................................................................................... 50 
2.3 Plasma analyses .................................................................................................... 50 
2.4 Glucose and insulin tolerance tests ....................................................................... 51 
2.5 Metabolic analyses ................................................................................................ 51 
2.6 Micro-computed tomography imaging ................................................................. 52 
2.7 Tissue sectioning and histology ............................................................................ 52 
2.8 Tissue lipid analysis .............................................................................................. 53 
2.9 Tissue gene expression ......................................................................................... 53 
2.10 Tissue protein expression ...................................................................................... 53 
2.11 Statistical analyses ................................................................................................ 54 
Chapter 3 ........................................................................................................................... 57 
3 Results .......................................................................................................................... 57 
3.1 Bempedoic acid attenuates the HFHC-induced elevation in body weight and 
adiposity ................................................................................................................ 57 
3.2 Bempedoic acid prevents hyperlipidemia ............................................................. 57 
3.3 Bempedoic acid prevents hepatic lipid accumulation ........................................... 63 
3.4 Bempedoic acid influences multiple metabolic pathways in the liver .................. 63 
3.5 Bempedoic acid improves hepatic lipid metabolism ............................................ 64 
3.6 Bempedoic acid prevents impaired glucose homeostasis ..................................... 73 
3.7 Bempedoic acid reduces inflammatory marker expression .................................. 73 
3.8 Bempedoic acid prevents atherosclerotic lesion development ............................. 87 
Chapter 4 ........................................................................................................................... 95 
4 Discussion .................................................................................................................... 95 
4.1 Interpretation and evaluation of results................................................................. 96 
4.1.1 Hyperlipidemia and tissue lipid accumulation .......................................... 96 
4.1.2 Glucose homeostasis ................................................................................. 97 
 ix 
 
4.1.3 Metabolic measures .................................................................................. 99 
4.1.4 Inflammation ........................................................................................... 101 
4.1.5 Atherosclerosis ........................................................................................ 103 
4.2 The question of mechanism ................................................................................ 103 
4.2.1 Comparison to related drugs and mouse models .................................... 103 
4.2.2 Comparison to clinical data .................................................................... 108 
4.3 Conclusions ......................................................................................................... 108 
References ....................................................................................................................... 110 
Curriculum Vitae ............................................................................................................ 158 
 x 
 
List of Tables 
Table 1-1 Lipoprotein classification ......................................................................................... 9 
Table 2-1: Mouse diets............................................................................................................ 48 
Table 2-3 Primary antibodies used for Western blotting and IHC ......................................... 55 
Table 2-4 Secondary antibodies used for Western blotting and IHC ..................................... 56 
 
 xi 
 
List of Figures 
Figure 1-1 Vessel structure and cell types ................................................................................ 5 
Figure 1-2 Atherogenesis .......................................................................................................... 6 
Figure 1-3 Hepatic insulin signaling ....................................................................................... 16 
Figure 1-4 Liver cell types and structure ................................................................................ 22 
Figure 1-5 General overview of inflammatory signaling pathways ....................................... 29 
Figure 1-6 Hepatic AMPK targets .......................................................................................... 36 
Figure 1-7 Mitochondrial and cytosolic acetyl-CoA as both a substrate and product ............ 40 
Figure 1-8 Hepatic effects of bempedoic acid. ....................................................................... 43 
Figure 2-1 Study design .......................................................................................................... 49 
Figure 3-1: Effects of BA on body weight and adiposity. ...................................................... 58 
Figure 3-2: Effects of BA on plasma lipids ............................................................................ 60 
Figure 3-3: FPLC analysis of the effects of BA on plasma lipids. ......................................... 61 
Figure 3-4: Effects of BA on hepatic lipids. ........................................................................... 65 
Figure 3-5: Effects of BA on liver size and function .............................................................. 67 
Figure 3-6: Effects of BA on the AMPK signaling pathway. ................................................. 68 
Figure 3-7: Hepatic effects of BA on metabolic gene expression. ......................................... 69 
Figure 3-8: Effects of BA on hepatic lipid metabolism. ......................................................... 71 
Figure 3-9: Effects of BA on glycemia. .................................................................................. 75 
Figure 3-10: Effects of BA on glucose homeostasis. .............................................................. 76 
 xii 
 
Figure 3-11: Effects of BA on hepatic inflammatory signaling pathways. ............................ 78 
Figure 3-12: Effects of BA on aortic inflammatory signaling pathways. ............................... 80 
Figure 3-13: Effects of BA on M1 inflammatory gene expression. ....................................... 82 
Figure 3-14: Effects of BA on M2 gene expression. .............................................................. 84 
Figure 3-15: Effects of BA on chronic inflammation. ............................................................ 86 
Figure 3-16: Effects of BA on atherosclerotic lesion development. ....................................... 88 
Figure 3-17: Effects of BA on aortic lipid accumulation. ...................................................... 90 
Figure 3-18: Effects of BA on atherosclerotic lesion morphology. ........................................ 92 
Figure 3-19: Effects of BA on atherosclerotic lesion apoptosis. ............................................ 94 
 
 xiii 
 
List of Abbreviations 
ABCA1 ATP-binding cassette transporter A1  
ABCG5 ATP-binding cassette transporter G5 
ACAT acyl-CoA: cholesterol acyl transferase  
ACC acetyl-CoA carboxylase  
ACL ATP-citrate lyase 
ACO fatty acyl-CoA oxidase 
ACS acyl-CoA synthetase 
ADP adenosine 5'-diphosphate 
AKT protein kinase B 
ALT alanine transaminase 
AMP adenosine 5'-monophosphate 
AMPK  AMP-activated protein kinase 
ANCOVA analysis of covariance 
ANOVA analysis of variance 
AP1 activating protein 1 
Apo apolipoprotein 
ApoB100 apolipoprotein B100 
AST aspartate transaminase 
ATGL adipose triglyceride lipase 
 xiv 
 
BA bempedoic acid (ETC-1002) 
cAMP cyclic-AMP 
CC3 cleaved caspase 3 
CD cluster of differentiation 
CE cholesteryl ester 
CETP cholesterol ester transfer protein  
CoA coenzyme A 
CPT1α carnitine palmitoyltransferase 1-alpha 
CRCT cAMP response element binding protein-regulated transcription coactivator 
CRP C-reactive protein  
CVD cardiovascular disease 
DAG diacylglycerol 
DAMP damage-associated molecular pattern molecule 
DGAT diacylglycerol acyltransferase  
DNA deoxyribonucleic acid 
ER  endoplasmic reticulum  
ERK1/2 extracellular related kinase 1/2  
FAS fatty acid synthase 
FC  free cholesterol  
FOXO1 forkhead box-O1 
 xv 
 
FPLC fast-performance liquid chromatography 
G6P glucose 6-phosphatase 
GS glycogen synthase 
GSK3 glycogen synthase kinase 3  
GTT glucose tolerance test 
H&E hematoxylin and eosin  
HDL high-density lipoprotein  
HFHC high-fat, high-cholesterol  
HMG-CoA 3-hydroxy-3-methyl-glutaryl-CoA  
HMGCR HMG-CoA reductase 
HMGCS HMG-CoA synthase 
hsCRP high sensitivity C-reactive protein 
HSL hormone sensitive lipase  
HTGL hepatic triglyceride lipase 
IDL intermediate-density lipoprotein  
IHC immunohistochemistry 
IKK inhibitor of IκBα kinase  
IL-1β interleukin 1-beta 
IL-6 interleukin 6 
INSIG insulin signaling gene 
 xvi 
 
IR insulin receptor 
IRS insulin receptor substrate 
ITT insulin tolerance test 
IκBα inhibitor of NF-κB-alpha 
JNK c-Jun N-terminal kinase 
LCAT lecithin: cholesterol acyl transferase 
LDL low-density lipoprotein 
LDL-C LDL cholesterol 
LDLR LDL receptor  
Ldlr-/-  LDLR knockout mice  
LPL lipoprotein lipase 
LPS lipopolysaccharide 
M1 classically activated macrophage 
M2 alternatively activated macrophage 
MAP2K mitogen-activated protein kinase kinase 
MAP3K mitogen-activated protein kinase kinase kinase 
MAPK mitogen-activated protein kinase  
mg/kg mg per kg body weight per day 
MMP matrix metalloproteinase 
MRI magnetic resonance imaging 
 xvii 
 
mTOR mammalian target of rapamycin 
mTORC1  mammalian target of rapamycin complex 1 
MTP microsomal triglyceride transfer protein  
NAFLD non-alcoholic fatty liver disease 
NASH non-alcoholic steatohepatitis  
Nf-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
non-HDL-C non-HDL-cholesterol 
NPC1L1 Neimann-Pick C1-like protein 1 
OCT Optimum Cutting Temperature 
ORO Oil red-O 
oxLDL oxidized LDL  
PAMP pathogen-associated molecular pattern molecule 
PBS phosphate buffered saline 
PCSK9 proprotein convertase subtilisin/kexin 9  
PEPCK phosphoenolpyruvate carboxykinase  
PGC1α PPAR-gamma coactivator 1-alpha  
PDK1 phosphoinositide-dependent kinase 1 
PI3K phosphatidylinositol 3-kinase  
PKC protein kinase C  
PPAR peroxisome proliferator-activated receptor 
 xviii 
 
PPRE PPAR response element 
PRAS40 proline-rich AKT substrate of 40 kDa 
PVDF polyvinylidene fluoride 
qRT-PCR quantitative real-time reverse transcriptase polymerase chain reaction 
RAPTOR regulatory associated protein of mTOR 
RCT reverse cholesterol transport 
RER respiratory exchange ratio 
ROS reactive oxygen species 
SAA serum amyloid A 
SCAP SREBP cleavage-activating protein  
SEM standard error of the mean 
SH2 Src homology 2 
SMA smooth muscle alpha-actin 
SMC smooth muscle cell 
SRB1 scavenger receptor B1  
SRE sterol response element  
SREBP sterol regulatory element-binding protein 
TC total cholesterol 
TCA tricarboxylic acid cycle 
TG  triacylglycerol 
 xix 
 
TLR4 toll-like receptor 4  
TNFα tumor necrosis factor alpha  
TRL triglyceride-rich lipoprotein 
TSC2 tubular sclerosis complex 2 
ULK unc 51-like kinase. 
UPR unfolded protein response 
UV ultraviolet 
VCO2 volume of carbon dioxide produced 
VLDL very low-density lipoprotein 
VO2 volume of oxygen consumed 
μCT micro-computed tomography 
 
1 
 
Chapter 1  
1 Review of thesis topics 
1.1 General Introduction 
Cardiovascular disease (CVD) continues to be a leading cause of death in developed 
countries, exacerbated in part by the increasing prevalence of Type 2 Diabetes and the 
metabolic syndrome (1, 2). The rates of CVD mortality have been declining over the 
previous decades due to significant advancements in our understanding of its 
pathophysiology and therapies for risk management (3, 4). Underlying the progression of 
CVD is atherosclerosis, a chronic inflammatory condition, which can develop silently for 
decades and not be identified until after a major cardiovascular event has occurred, such 
as myocardial infarction, stroke, or peripheral artery disease (1, 5). 
1.2 Cardiovascular Disease and Dyslipidemia 
It has been known for some time now that cholesterol plays a major role in the 
development of CVD and over the past century there have been huge advancements in 
our understanding of this relationship (4). However, in addition to its role in CVD 
progression it is important for many other bodily functions, both as a structural and 
signaling molecule. Cholesterol is required for the synthesis of steroid hormones, bile 
acid, fat soluble vitamins and myelin sheath while also serving as a major structural 
component of cell membranes (6, 7).  
Cholesterol traveling within the circulation is packaged into small micelle particles 
known as lipoproteins (further characterized in section 1.2.2). Low- and high-density 
lipoproteins (LDL and HDL, respectively) are two of the classes of lipoproteins by which 
cholesterol is transported within the circulation. Plasma LDL cholesterol (LDL-C) or 
non-HDL cholesterol (HDL-C) have been established for some time as major risk factors 
for CVD (8, 9). For example, evidence from randomized clinical trials examining statin 
efficacy have demonstrated that for every 1 mmol/L lowering in LDL-C, there was a 22% 
reduction in major vascular events and a 10% reduction in all-cause mortality (10). An 
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LDL-C concentration >5.0 mmol/L would be considered severe dyslipidemia likely due 
to a genetic disorder and warrant pharmacological treatment (11, 12). HDL-C has long 
been thought to be cardioprotective but more recently, multiple therapies that 
pharmacologically raise HDL have so far failed to demonstrate therapeutic benefit (13). 
Clinicians will typically measure plasma LDL-C and HDL-C concentrations both to 
estimate CVD risk and to gauge efficacy of treatment. 
Dyslipidemia consists of elevated plasma LDL-C (hypercholesterolemia) and TG 
(hypertriglyceridemia) and low HDL-C and thus increases the risk of developing CVD. It 
can either be of genetic origin or secondary to other factors such as age, obesity, diabetes, 
and metabolic syndrome (14, 15). This lipid profile often seen in diabetics is referred to 
as diabetic dyslipidemia which, at least in part explains why patients with diabetes are at 
a much greater risk for developing CVD (16, 17). 
The high incidence of CVD is linked to, and likely driven by the increasing prevalence of 
so-called “diseases of affluence” such as insulin resistance (leading to Type 2 Diabetes), 
obesity, and hepatic steatosis, all of which play a role in the development of atherogenic 
dyslipidemia and CVD (18–20). This cluster of risk factors, along with high blood 
pressure, have become known as the metabolic syndrome (15, 21). The patient population 
represented by this clustering of cardiometabolic abnormalities has been increasing in 
prevalence for some time, and will likely continue to do so thereby representing a 
significant challenge when it comes to managing the worldwide CVD burden (22). 
Altogether, there is a growing need for therapies that will further lower LDL (or non-
HDL) cholesterol while also treating other risk factors associated with the metabolic 
syndrome. The standard of care used clinically has improved tremendously over the years 
and there are several experimental therapies with significant therapeutic potential in late 
stage clinical development (reviewed in section 1.7). However, in order to counter the 
increasing CVD prevalence, there is a need for a better understanding of the molecular 
pathways that govern disease progression in order to identify novel therapeutic targets. 
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1.2.1 Atherogenesis 
Vessels that are most susceptible to atherosclerosis are the medium and large sized 
arteries. The structure of a normal artery is shown in Figure 1-1. On the most basic level, 
it consists of an outermost, collagen-rich layer (adventitia), followed by an elastic middle 
layer (media), then a thin innermost layer (intima) facing the vessel lumen and exposed to 
continuous blood flow (Figure 1-1). Additionally, the medial layer is lined externally and 
internally by the external and internal elastic membranes, respectively (23). Each layer is 
defined by their cell types and macromolecule extracellular matrix composition. The 
intima is a thin layer of endothelial cells surrounded by a subendothelial space comprised 
of extracellular matrix proteins such as collagen and elastin. Humans and other larger 
mammals also contain smooth muscle cells (SMCs) within the intima in contrast to 
model organisms such as rodents, which do not (23, 24). The internal elastic membrane 
marks the start of the media. This thick elastin-rich layer made up of many SMCs and 
extends until the external elastic membrane (25). Lastly, the adventitial layer contains a 
heterogeneous combination of cells including vascular progenitor cells, fibroblasts and 
resident arterial macrophages. High collagen content within the adventitia provides 
tensile strength to the arteries (25–27). 
The initiation of atherogenesis begins when apolipoprotein (apo) B-containing 
lipoproteins circulating in the blood enter the arterial intima (Figure 1-2A). This occurs 
predominantly in arteries experiencing oscillatory, non-uniform, and lower velocity flow 
(28). While in the subendothelial space lipoproteins will interact with the extracellular 
matrix leading to their retention and modification. Oxidative modification by reactive 
oxygen species (ROS) or lipoxygenases of lipids and LDL (oxLDL) elicits immune 
responses and complex interactions with and between the endothelial cells, SMCs, and 
immune cells (29, 30). Endothelial cells will express adhesion molecules and secrete 
chemokines resulting in the recruitment of leukocytes (mostly monocytes) to the area of 
lipid deposition. Within the arterial intima, monocytes will differentiate into macrophage 
and phagocytose (engulf) accumulated oxLDL particles, generating lipid-loaded foam 
cells (31) (Figure 1-2A). Lipid deposition within the intima, referred to as fatty streaks, 
accumulates over time resulting in the thickening of the intimal space forming a growing 
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atherosclerotic plaque (Figure 1-2B). Plaque development continues with the infiltration 
and proliferation of SMCs from the media and monocytes from the circulation (Figure 1-
2C). Cellular apoptosis and the accumulation of debris and cholesterol crystals lead to the 
formation of a necrotic core. SMCs secrete collagen to generate a fibrous cap overlaying 
the growing plaque and conferring stability (31–33) (Figure 1-2D). Several factors can 
lead to the destabilization, erosion and potential rupture of the plaque fibrous cap, 
including a growing necrotic core, collagen degradation by enzymes such as matrix 
metalloproteases (MMPs), along with plaque neovascularization, microcalcification and 
remodeling (32–36). Plaque rupture exposes the highly thrombotic necrotic core to the 
blood (Figure 1-2E). Clinically, this can lead to the sudden onset of major vascular events 
as the thrombi can  occlude the lumen or break off from the plaque and occlude distal 
arteries in locations such as the heart or brain, presenting clinically as a myocardial 
infarct or stroke, respectively (5, 29, 36).  
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Figure 1-1 Vessel structure and cell types 
A blood vessel consists of three main layers: the outermost, collagen-rich layer 
(adventitia), the elastic middle layer (media), and the thin, innermost layer (intima) facing 
the vessel lumen. Each of these layers are separated by elastic membranes and are further 
characterized by unique cell types (21-25). 
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Figure 1-2 Atherogenesis 
The development of atherosclerosis occurs over several decades, beginning early in life 
when lipoproteins circulating in the blood enter the arterial intima. Once here, monocytes 
will differentiate into macrophage and phagocytose accumulated oxidized LDL particles, 
generating foam cells (A). Continued lipid deposition within the intima generates fatty 
streaks, resulting in the thickening of the intimal space forming a growing atherosclerotic 
plaque (B). Plaque development continues with the infiltration and proliferation of 
smooth muscle cells from the media which begin to secrete collagen to stabilize the 
growing plaque (C). Cellular apoptosis and the accumulation of debris and cholesterol 
crystals lead to the formation of a necrotic core (C). Continued secretion of collagen 
generates a fibrous cap overlaying the growing plaque and conferring stability, while the 
necrotic core can continue to grow (D). Thinning of the fibrous cap causes destabilization 
of the plaque and increases its susceptibility to rupture. Plaque rupture exposes the highly 
thrombotic necrotic core to the blood (E). Thrombi formation can occlude blood vessels 
and rapidly lead to serious clinical events (26-34). 
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1.2.2 Lipoproteins 
In addition to cholesterol, lipoproteins contain triacylglycerol, phospholipids and 
proteins, the ratios of which determine the density and thus classification of the 
lipoprotein. They are spherical particles with an outer hydrophilic monolayer of free 
cholesterol, phospholipids, and apolipoproteins surrounding a hydrophobic core of 
triacylglycerol (TG) and cholesteryl ester (CE). Lipoprotein solubility allows for the 
transportation of insoluble hydrophobic lipids within the circulation throughout the body 
(37). 
In addition to different lipid composition, lipoprotein classes also differ in terms of size, 
density, and the types of apolipoproteins with which they associate. The largest, lowest 
density class of lipoproteins are chylomicrons which originate from the intestine and 
contain predominantly dietary TG with a small amount of CE derived from the diet or 
reabsorbed biliary cholesterol. Very low-density lipoproteins (VLDL) are synthesized by 
the liver and its core contains primarily TG plus a greater amount of CE content than 
chylomicrons. Hydrolysis of chylomicron and VLDL TG result in smaller, denser 
particles referred to as chylomicron remnants and intermediate-density lipoproteins 
(IDL), respectively. Collectively, chylomicrons and their remnants, IDL, and VLDL all 
contain apoB and are referred to as triglyceride-rich lipoproteins (TRLs). Further removal 
of IDL-TG by hepatic lipase leads to the formation of LDL, which contains a relatively 
high CE content. Lastly, high-density lipoproteins (HDL) also contains a high CE content 
but serve a unique function known as reverse cholesterol transport, which delivers 
cholesterol from peripheral tissues back to the liver for potential excretion as bile (37, 
38). Further characterization of the classes of lipoproteins in terms of composition, 
origin, associated apolipoproteins, and function are described in Table 1-1 and their 
metabolism is summarized in section 1.3.   
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Table 1-1 Lipoprotein classification 
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1.3 Lipoprotein Metabolism 
Lipoproteins can either be formed from exogenous dietary lipids in intestinal cells 
(enterocytes), or from de novo synthesis in liver cells (hepatocytes). 
1.3.1 Enteric lipoprotein production from exogenous lipids  
Dietary lipids are readily absorbed by small intestine enterocytes for packaging into 
chylomicrons for transport throughout the body. In the gut, dietary TG is hydrolyzed by 
pancreatic lipases to free fatty acids and monoacylglycerol while CE is hydrolyzed to a 
free cholesterol and free fatty acid (39). Following entry into the enterocyte via active 
and passive transporters, these lipids are re-esterified into TG and CE to be packaged into 
chylomicrons. Microsomal triglyceride transport protein (MTP) facilitates chylomicron 
formation by loading lipids onto the scaffolding protein apoB48. The fully-formed, TG-
rich chylomicron is secreted from the enterocyte into the lymphatics, eventually entering 
the bloodstream. Within the lymphatics and circulation, chylomicrons become enriched 
with apolipoproteins E and C. Now the fully-formed chylomicron particle contains 
apolipoproteins B48, CI, CII, CIII, and E and will circulate to peripheral tissues for 
further metabolism (section 1.3.3) (39–42).  
1.3.2 Hepatic lipoprotein production 
The liver acts as a central mediator of lipid homeostasis by controlling the production of 
lipoproteins to be secreted for use by the rest of the body. This involves the formation of 
apoB100 containing particles known as VLDL. TG for export are synthesized from free 
fatty acids derived from either chylomicrons, adipose tissue TG, or from de novo 
synthesis (lipogenesis). Cholesterol to be exported can be chylomicron-derived from the 
exogenous pathway but the majority of cholesterol in the body is synthesized de novo by 
the liver (reviewed in section 1.4).  
Similar to apoB48 and chylomicrons, apoB100 serves as the scaffold for hepatic VLDL 
synthesis. Newly synthesized apoB100 peptides are rapidly degraded if there is low TG 
availability. When TG is available, apoB100 is co-translationally lipidated with TG, CE, 
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and phospholipids by MTP in the endoplasmic reticulum (ER) lumen. The newly 
assembled VLDL particle can now be secreted from the hepatocyte. Constant synthesis 
and degradation of apoB peptides in enterocytes and hepatocytes allows for the rapid 
export of lipoprotein particles when there is a sudden influx of intracellular TG (43).  
HDL production occurs in the circulation after the hepatic synthesis and secretion of 
apoAI. Free apoAI binds to ATP-binding cassette (ABC)-A1 (ABCA1) on the surface of 
peripheral tissues which facilitates the loading of phospholipid and free cholesterol. This 
generates a discoidal particle known as pre-β HDL, which can undergo further lipidation 
by ABCG1 and cholesterol esterification by lethicin-cholesterol acyltransferase (LCAT) 
generating more mature, spherical HDL particles (44, 45). 
1.3.3 Metabolism of circulating lipoproteins  
As chylomicrons and VLDL travel through the circulation, lipoprotein lipase (LPL) 
hydrolyses the lipoprotein TG. LPL resides on the luminal surface of endothelial cells 
lining capillaries that perfuse adipose, cardiac, and skeletal muscle tissue. Released free 
fatty acids are taken up by the peripheral tissues, a processes requiring apoCII as an LPL 
cofactor. As already mentioned, hydrolysis of the core TG within chylomicrons and 
VLDL results in the formation of a smaller and denser particle referred to as chylomicron 
remnants and IDL, respectively. IDL can be further metabolized by hepatic lipase to form 
CE-rich LDL. These lipoproteins remain in the circulation until being cleared by 
endocytosis at the liver and peripheral tissues. LDL is cleared by the LDL receptor 
(LDLR) using apoB as the receptor ligand while IDL is cleared by LDLR-related proteins 
using apoE as the receptor ligand (37, 38, 42, 46). 
Circulating HDL has two ways of delivering cholesterol back to the liver for reverse 
cholesterol transport.  First, hepatic scavenger receptor B1 (SRB1) binds to and removes 
CE from HDL particles. Otherwise, cholesterol ester transfer protein (CETP) mediates a 
lipid exchange between HDL and TRLs. Specifically, CE from HDL is exchanged for TG 
from TRLs. This results in CE-rich apoB-containing lipoproteins (such as chylomicron 
remnants, IDL and LDL) which can subsequently be taken up by the liver. HDL gains 
TG from the TRLs which can be hydrolyzed by hepatic lipase. TG-rich HDL has reduced 
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affinity for apoA1 favoring their dissociation. The lipid-poor apoA1 can now be lipidated 
again by ABCA1 to form new HDL, creating a cycle of HDL-CE transport from 
peripheral tissues to the liver (13, 37, 38). 
1.4 Hepatic Fatty Acid and Cholesterol Metabolism 
Hepatic de novo lipogenesis of cholesterol and TG both use cytosolic acetyl-CoA as their 
initial substrate. Acetyl-CoA is not only a substrate for several anabolic processes, it can 
be derived from a variety of catabolic ones such as glycolysis and fatty acid β-oxidation 
(47). From acetyl-CoA the lipogenesis pathways diverge and acetyl-CoA enters either the 
cholesterol or fatty acid biosynthetic pathways. 
1.4.1 Cholesterol synthesis 
The cholesterol biosynthetic pathway begins with the formation of acetoacetyl-CoA from 
two acetyl-CoA molecules followed by the addition of another acetyl-CoA molecule to 
create 3-hydroxy-3-methylglutarate-CoA (HMG-CoA). The next step has a clinical 
significance that is difficult to overstate. The conversion of HMG-CoA to mevalonate by 
HMG-CoA reductase (HMGCR) represents both the rate-limiting and first committed 
step of cholesterol and isoprenoid biosynthesis. This made way for the discovery of 
HMGCR inhibitors, known as statins that are in widespread clinical use today (reviewed 
in section 1.7.1). Mevalonate is converted into isoprene units which are subsequently 
polymerized into a 30-carbon long squalene chain. Finally, squalene is cyclized followed 
by additional modifications to yield a 27-carbon cholesterol molecule (48, 49). 
1.4.2 Fatty acid synthesis 
Fatty acid synthesis by de novo lipogenesis also begins with acetyl-CoA which is 
carboxylated by acetyl-CoA carboxylase (ACC) to form malonyl-CoA. The fatty acid 
synthase (FAS) complex adds additional units of acetyl-CoA to malonyl-CoA to generate 
an acyl-CoA. With subsequent additions of acetyl-CoA, FAS generates the 16-carbon 
acyl-CoA known as palmitic acid. Palmitic acid can undergo unsaturation or further 
elongation followed by esterification with glycerol to form monoacylglycerol. The 
further esterification of one or two more fatty acids results in the formation of 
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diacylglycerol and triacylglycerol, respectively. Triacylglycerol, or TG is the primary 
means of fatty acid storage and transport, as the hepatocyte can store them in lipid 
droplets or export them as VLDL (2, 50, 51). 
1.4.3 Sterol response element-binding proteins 
Another important layer in the regulation of lipid synthesis is the sterol response element-
binding protein (SREBP) pathway.  SREBP is a transcription factor encoded by two 
genes, SREBP1 and SREBP2. The former generates two isoforms due to alternative 
splicing, SREBP-1a and SREBP-1c. Generally, the active SREBP-1c protein  regulates 
genes involved in the synthesis of fatty acids while SREBP-2 deals more so with 
cholesterol synthesis gene expression and SREBP-1a regulates both (52).  
SREBPs are translated into their full length, endoplasmic reticulum-bound precursor 
form where they remain in proximity to the SREBP-cleavage activating protein (SCAP) 
and are held in place by the insulin-induced gene (Insig). When intracellular sterols are 
low or depleted, Insig releases SCAP which translocates the membrane-bound SREBP to 
the Golgi apparatus. Here proteolytic processing releases the SREBP protein from the 
Golgi membrane in its active form. It can now translocate to the nucleus where it 
promotes lipogenic gene expression by recognizing sterol receptor elements (SREs) 
within the promotors of target genes. Additionally, active SREBPs can further upregulate 
their own gene expression due to SREs located within their own promoter regions (52, 
53). 
1.4.4 Fatty acid oxidation 
Hepatocytes process intracellular free fatty acids by both esterification into TG 
(described above) and also through fatty acid β-oxidation. In a process similar to the 
reverse of fatty acid synthesis, β-oxidation breaks down free fatty acids in cycles, where 
the fatty acid is shortened by one acetyl-CoA unit at a time. This acetyl-CoA can then be 
fully broken down to carbon dioxide and water in the tricarboxylic acid cycle or 
condensed into ketone bodies and secreted into the circulation (54).  
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To protect cells against fatty acid-induced lipotoxicity (see section 1.6.3.1), fatty acid β-
oxidation is tightly-regulated in conjunction with esterification into TG for either storage 
or export as VLDL. β-oxidation can only occur inside the mitochondria matrix and while 
short and medium chain fatty acids can freely diffuse through the mitochondrial 
membrane, long-chain fatty acids (such as palmitoyl-CoA) cannot. Instead, carnitine 
palmitoyl transferase (CPT)-1α must first convert the long-chain acyl-CoA to an acyl-
carnitine to allow for transfer across the mitochondria membrane. Once inside the 
mitochondria matrix CPT2 converts the acyl-carnitine back into a long-chain acyl-CoA, 
which can now undergo β-oxidation (16, 55).  
The rates of de novo fatty acid synthesis and fatty acid β-oxidation are coordinated in 
such a way as to prevent futile cycling where a free fatty acid is broken down into acetyl-
CoA subunits just to be re-synthesized back into a free fatty acid. This regulation is 
mediated by malonyl-CoA, the product of ACC from the first step of fatty acid synthesis 
(section 1.4.2). CPT1α is inhibited by malonyl-CoA, thus suppressing β-oxidation by 
preventing long-chain acyl-CoA from entering the mitochondria matrix (54, 56). This 
coordination between the rates of fatty acid synthesis and β-oxidation is important for 
proper regulation of energy flux, in instances such as transitioning from fasting to 
feeding. 
In addition to the mitochondria, peroxisomes are a second site of β-oxidation. Very long-
chain fatty acids, typically greater than 20 carbons, must be metabolized by peroxisomal 
β-oxidation. This process generates a shorter acyl-CoA which can subsequently undergo 
mitochondrial β-oxidation. Acyl-CoA oxidase (ACO) is the rate-limiting enzyme in 
peroxisomal β-oxidation and ACO deficiency results in the accumulation of very long 
chain fatty acids (57–59). 
1.5 Hepatic Insulin Signaling 
Insulin is a peptide hormone essential for driving the body’s metabolic response 
following the ingestion of a meal. It is secreted by pancreatic β-cells into the circulation 
after feeding and signals to peripheral insulin-sensitive tissues such as adipose, liver, and 
muscle. Insulin signaling is initiated when insulin binds to and activates the insulin 
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receptor (IR) activating its tyrosine kinase and promoting phosphorylation of the insulin 
receptor substrate (IRS). This allows for docking of proteins containing Src homology 2 
(SH2) domains such as phosphoinositol 3-kinase (PI3K) which becomes active. PI3K 
activates phosphoinositide-dependent kinase 1 (PDK1) which phosphorylates and 
activates Protein Kinase B (AKT), a central mediator of the metabolic effects of insulin. 
Active AKT phosphorylates different targets relating to glucose and lipid metabolism 
(Figure 1-3, sections 1.5.1, 1.5.2) (50, 60, 61).  
1.5.1 Regulation of glucose metabolism 
The primary function of insulin on the liver is to suppress hepatic gluconeogenesis during 
the fed state. Active AKT phosphorylates and inhibits the transcription factor forkhead 
box-O1 (FOXO1) resulting in its exclusion from the nucleus. This prevents FOXO1-
mediated transcription of gluconeogenic genes such as glucose 6-phosphatase (G6P) and 
phosphoenolpyruvate carboxykinase (PEPCK) (Figure 1-3). However, this model does 
not explain how insulin can acutely regulate gluconeogenesis since it has been known for 
some time that insulin rapidly suppresses hepatic glucose output well before any changes 
in both G6P or PEPCK protein expression are observed (60). Very recent evidence 
suggests that this could be explained by effects of insulin outside the liver. An additional 
function of insulin is to inhibit adipose tissue lipolysis, thus reducing the flux of free fatty 
acids and glycerol to the liver. Perry, et al. (62) demonstrate that adipose tissue-derived 
acetyl-CoA (from free fatty acid β-oxidation) and glycerol serve as the primary 
gluconeogenic substrates used by the liver. Thus, in response to insulin administration, 
rapid inhibition of adipose tissue lipolysis was responsible for the acute suppression of 
hepatic glucose production. More simply put, insulin acutely suppresses hepatic 
gluconeogenesis through an extra-hepatic mechanism. 
Another function of hepatic insulin signaling relating to glucose metabolism is the 
stimulation of glycogen synthesis. AKT phosphorylates and inhibits glycogen synthase 
kinase-3 (GSK3), which is an inhibitor of glycogen synthase (GS). Therefore, GS is 
active and under fed conditions will convert glucose into glycogen for storage (63) 
(Figure 1-3). 
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Figure 1-3 Hepatic insulin signaling 
Insulin binds to the insulin receptor (IR) leading to activation of insulin receptor 
substrates (IRS) by tyrosine phosphorylation (pY). This leads to activation of 
phosphoinositol 3-kinase (PI3K) which recruits Protein Kinase B (AKT) inducing its 
serine (pS) and threonine (pT) phosphorylation by phosphoinositide-dependent kinase 1 
(PDK1). Active AKT phosphorylates several targets which regulate glucose and lipid 
metabolism. Forkhead Box-O1 (FOXO1) phosphorylation results in its nuclear exclusion 
preventing it from upregulating gluconeogenic gene expression. Proline-rich AKT 
substrate of 40 kDa (PRAS40) and tuberous sclerosis complex 2 (TSC2) phosphorylation 
blocks inhibition of mammalian target of rapamycin complex 1 (mTORC1) which can 
activate the lipogenic transcription factor sterol regulatory element binding protein-1c 
(SREBP1c). Additionally, AKT also promotes glycogen synthesis by phosphorylating 
and inhibiting glycogen synthase kinase-3 (GSK3), which is an inhibitor of glycogen 
synthase (GS). 
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1.5.2 Regulation of lipid metabolism 
Hepatic insulin signaling also triggers de novo lipogenesis (section 1.4) through the 
P13K-AKT pathway, especially during periods of excess nutrient availability. When 
AKT is phosphorylated and activated by insulin it phosphorylates a number of targets 
ultimately leading to increased activity of the lipogenic transcription factor SREBP-1c 
(64). Insulin increases SREBP-1c expression through the activation of the mammalian 
target of rapamycin complex (mTORC)-1. This is done by AKT phosphorylating and 
inhibiting two upstream inhibitors of mTORC1, proline-rich AKT substrate of 40 kDa 
(PRAS40) and tuberous sclerosis complex 2 (TSC2) (Figure 1-3) (64). 
Additionally, insulin inhibits lipoprotein secretion, even while stimulating de novo 
lipogenesis via inhibition of FOXO1. Besides promoting gluconeogenic gene expression, 
FOXO1 also promotes the transcription of MTTP and APOC3. The MTP protein 
(described in sections 1.3.2 and 1.3.3) is responsible for the assembly of lipoproteins by 
loading TG onto apoB. Reducing MTP expression thus limits lipoprotein synthesis and 
secretion. ApoCIII is thought to play a role in subsequent lipoprotein synthesis and 
secretion, so limiting its expression can further inhibit lipoprotein production (65, 66). 
1.5.3 Insulin resistance and Type 2 Diabetes 
Insulin resistance is one of the components of the metabolic syndrome and it describes 
the state where tissues fail to appropriately respond to insulin. The pancreas compensates 
for this by increasing insulin production, creating a state known as hyperinsulinemia. 
With time this can develop into Type 2 Diabetes. The body now cannot regulate glucose 
homeostasis due to an inability to synthesize insulin. Extreme hyperglycemia ensues 
which is life-threatening and must be managed with exogenous insulin injections (67).  
The result of insulin resistance with hyperinsulinemia depend on the organ system 
effected. In adipose tissue, insulin fails to suppress TG lipolysis, thus increasing 
circulating free fatty acids. In muscle, insulin fails to upregulate glucose transporter type 
4 (GLUT4) translocation to the cell membrane limiting muscle glucose uptake resulting 
in hyperglycemia. Most notably, in liver insulin fails to suppress gluconeogenesis while 
continuing to  stimulate lipogenesis, creating the phenotype seen in patients with diabetes 
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of hyperinsulinemia, hyperglycemia, and hyperlipidemia (68). This paradoxical effect 
was suggested to be due to a bifurcation in the insulin signaling pathway, where AKT 
fails to inhibit FOXO1 and gluconeogenic gene expression while continuing to stimulate 
the mTORC1-SREBP1c lipogenic pathway (69–72). However, insulin resistance is 
typically thought to occur by serine phosphorylation of IRS1, an inhibitory event which 
dampens insulin signaling through the PI3K-AKT pathway, which should in theory effect 
all targets of AKT, not just FOXO1. Insulin resistance characterized by IRS-1 serine 
phosphorylation occurs via multiple mechanisms such as MAPK signaling (a negative 
feedback effect of insulin signaling) and protein kinase C-ε (PKCε) activation by 
lipotoxic intermediates such as diacylglycerol (DAG) (2, 50, 67, 73). More recent 
evidence suggests that the observed stimulation of both gluconeogenesis and lipogenesis 
despite reduced insulin sensitivity may be a result of increased nutrient flux to the liver, 
as is seen with insulin resistance (60, 62, 74, 75). Indeed, the increased adipose tissue-
derived free fatty acid flux to the liver seen in insulin resistance has been shown to be the 
major driver of hepatic TG synthesis (75) and glucose production (62) independent of 
insulin signaling. 
1.6 Hepatic Steatosis and Inflammation 
Tightly linked to conditions such as insulin resistance, obesity, and dyslipidemia is the 
process of hepatic steatosis, or the accumulation of fat in the liver. Also factoring into 
these metabolic conditions and CVD risk factors is inflammation, although the role this 
plays is much more difficult to define. 
1.6.1 Normal liver biology and morphology 
The liver is responsible for many functions vital for survival. In addition to regulating 
glucose, lipid, and lipoprotein metabolism (discussed in previous sections), other 
functions involve synthesis (bile acids, albumen, clotting factors, hormones, other 
proteins), storage (glycogen, vitamins), and metabolism (prodrugs, toxins, ammonia, 
bilirubin). While not fully comprehensive, this list does demonstrate some of the 
functions that the liver is involved in such as digestion, oncotic pressure maintenance, 
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clotting, nutrient storage, drug metabolism, detoxification, the urea cycle, and the 
removal of other waste (76, 77). 
So far, when referring to the liver it is usually the hepatocyte being described. 
Hepatocytes make up approximately 80% of the liver by mass and are responsible for 
most functions attributed to the liver. However, the liver has a very complex 
morphological structure which contains several additional cell types organized into 
lobules (Figure 1-4). The hepatic artery and portal vein deliver blood from the arteries 
and intestine, respectively. These arrange alongside bile ducts forming what are called 
portal triads. Blood flow from both the hepatic artery and portal vein enters the region 
known as the sinusoid, which drains to the central vein and exits the liver. Liver lobules 
are organized in hexagonal structure with six portal triads surrounding a central vein 
(Figure 1-4). 
The lobule structure seen in the liver consists of several cell types in addition to 
hepatocytes, shown in Figure 1-4. First, sinusoid endothelial cells make up the lining of 
the vasculature, separating hepatocytes from the sinusoid, where blood flow occurs (78). 
The resulting area between the hepatocytes and sinusoid endothelial cells is referred to as 
the space of Disse. Cholangiocytes are biliary epithelial cells lining the bile ducts into 
where hepatocytes secrete bile acid and cholesterol for digestion by facilitating micelle 
formation and lipid absorption (79). Kupffer cells (or Ido cells) are liver-specific 
macrophage thought to originate from circulating monocytes and thus are for host 
immune defense (80). Hepatic stellate cells are important for the storage of most of the 
body’s retinoids (such as vitamin A). Additionally, during liver injury they transition into 
an “activated” state characterized by increased proliferation, contractility, and collagen 
secretion, contributing to liver fibrosis (81). These are the major cell types involved in 
liver function but there are several others including lymphocytes, neuroendocrine cells, 
blood cells, and smooth muscle cells (76). 
Due to the highly lipogenic nature of the liver, it can store excess lipid as TG-rich lipid 
droplets. Hepatocyte lipid balance, or lipid droplet content is determined by four main 
processes (82): 
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1) Delivery of exogenous lipid to the liver (section 1.3.1). This would include lipid 
from circulating free fatty acids and apoB-containing lipoproteins. 
2) De novo synthesis of lipid within the liver (section 1.4.2). 
3) Export of lipid by VLDL secretion (section 1.3.2). 
4) Metabolism of lipid by fatty acid β-oxidation (section 1.4.4). 
The rates of 1) and 2) contribute to hepatic lipid storage which is opposed by lipid 
removal through the rates of 3) and 4). Hepatic TG is relatively inert and not particularly 
harmful. In contrast, free fatty acids and other lipid intermediates can result in 
lipotoxicity, so hepatocytes will promote their esterification in TG. However, hepatocytes 
have a limited capacity to store TG-rich lipid droplets before hepatic dysfunction can 
start to occur. 
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Figure 1-4 Liver cell types and structure 
The liver and its various cell types are arranged into structures known as lobules. The 
hepatic artery and portal vein deliver blood from the arteries and intestine, respectively, 
which flows into the sinusoid. The bile duct is located near the hepatic artery and portal 
vein to form a portal triad. Blood flow through the sinusoid drains to the central vein and 
exits the liver. Liver lobules are organized in hexagonal structure with six portal triads 
surrounding a central vein (74-77). 
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1.6.2 Non-alcoholic fatty liver disease 
Hepatic steatosis occurring in the absence of alcohol is clinically referred as non-
alcoholic fatty liver disease (NAFLD). If the rates of lipid delivery to the liver and de 
novo lipogenesis within the liver are not matched by rates of fatty acid β-oxidation and 
VLDL secretion, then hepatocytes will increase lipid droplet formation and NAFLD will 
ensue. NAFLD is thought to be the hepatic manifestation of the metabolic syndrome due 
to its tight association with obesity, dyslipidemia, and type 2 diabetes (83). NAFLD 
encompasses a spectrum of disorders from simple steatosis to steatohepatitis (covered in 
the next section) which can progress to more severe conditions such as cirrhosis, which is 
irreversible and greatly increases the risk of developing hepatocellular carcinoma (83).  
NAFLD is largely asymptomatic in its early stages, especially when present as only 
simple steatosis. The gold standard for diagnosis is a liver biopsy, despite efforts to 
develop less invasive diagnostic methods. Liver biopsy is subject to sampling error, 
subjective interpretation of results, and a small chance of complications (83–85). 
Developing means of non-invasive NAFLD diagnosis has been met with varying degrees 
of success and include imaging modalities, plasma markers, and scoring algorithms. The 
major drawbacks of these methods is both low sensitivity (false negatives) and specificity 
(false positives). Imaging can be done with ultrasound, computed tomography (CT) or 
most accurately with magnetic resonance imaging (MRI) (86) as well as derivations of 
these technologies such as transient elastography, or FibroScan® (87). Plasma markers 
that can be looked at to assess liver function include alanine and aspartate transaminases 
(ALT and AST, respectively), albumen, platelet count, glucose, insulin, TG, and 
cholesterol (85, 86). There are also many scoring algorithms which take these plasma 
measurements into account, in addition to age, gender, body mass index, insulin 
resistance and glycemia, hypertension, and the results from the imaging tools previously 
mentioned (85, 86). All of these methods for the diagnosis of NAFLD, or more severe 
steatohepatitis and fibrosis, are susceptible to giving false positive results (especially with 
comorbidities) or simply failing to detect NAFLD, especially when in its earliest stages. 
By the time clinicians are presented with enough evidence to warrant a biopsy, the liver 
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disease could have progressed to much more advanced and serious stages, described in 
the next section. 
1.6.3 Non-alcoholic steatohepatitis and inflammation 
NAFLD progression to its most serious form, termed nonalcoholic steatohepatitis 
(NASH), is in most general terms hallmarked by increased inflammation and fibrosis 
(86). Histologically it presents as simple steatosis (as is the case for NAFLD) with the 
additions of hepatocyte ballooning, monocyte infiltration, and collagen deposition (not 
seen with early NAFLD) (88). The increase in fibrosis and inflammation seen with 
NASH greatly increases one’s risk to progress to hepatocellular carcinoma and liver 
failure. The features of NASH stem from the lipid imbalances which characterized 
NAFLD but when left unchecked these further lead to NASH through several potential 
mechanisms. These include lipotoxicity, endoplasmic reticulum (ER) stress, oxidative 
stress, immune activity, and endotoxin and cytokine signaling (86), each described briefly 
below.  
1.6.3.1 Lipotoxicity 
When the liver’s mechanisms for mitigating the accumulation of free fatty acids become 
overwhelmed, lipotoxicity ensues. Excess fatty acids can induce ER stress, reactive 
oxygen species (ROS) production and oxidative stress, and insulin resistance from 
lipotoxic intermediates such as diacylglyceride (DAG) and ceramides (89, 90). These 
mechanisms collectively increase hepatic inflammation, cellular apoptosis and necrosis, 
fibrosis, and the progression of NAFLD to NASH.  
1.6.3.2 ER stress 
Membrane and secreted proteins are synthesized and folded within the ER lumen. When 
the accumulation of unfolded proteins exceeds the ER’s capacity, ER stress ensues. The 
ER stress response, or unfolded protein response (UPR) is an adaptive mechanism for 
cells to restore intracellular homeostasis. Activation of the UPR results in an overall 
reduction in protein synthesis, increased lipogenesis for ER membrane expansion, 
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induction of autophagy to recycle unfolded proteins, and the activation of various 
inflammatory cascades (89, 91).  
1.6.3.3 Reactive Oxygen Species 
An increase in reactive oxygen species (ROS) can lead to oxidative stress. ROS can be 
generated by lipotoxicity and the UPR which add to the already high ROS production by 
hepatocyte fatty acid oxidation (89). Excess oxidative stress can lead to nuclear and 
mitochondrial DNA damage and elevated proinflammatory cytokine production (89). 
1.6.3.4 Immune responses 
The innate immune system plays a major role in NASH development and progression to 
more serious diseases of the liver. The temporal relationship of the key events that 
culminate in NASH are not well understood.  During the development of NASH, there is 
an increase in infiltration of circulating immune cells while endogenous Kupffer cells 
transition to a proinflammatory or “activated” phenotype. Possibly driving this is the 
chronic, low-grade inflammation and elevations in circulating cytokines seen during 
obesity, insulin resistance, and the metabolic syndrome (80). Additionally, dietary 
components (such as fats and fructose) can augment the microbiota within the gut and 
increase the production of endotoxins such as lipopolysaccharide (LPS). The same 
dietary factors can increase gut permeability and lead to elevations in circulating 
endotoxin concentrations (80, 92). Via the portal vein, endotoxins from the gut will first 
go to the liver, where LPS activates cell surface receptors triggering an inflammatory 
response (93). 
The inflammatory responses of Kupffer cells and other immune cell types throughout the 
body are best characterized by an increase in the production and secretion of cytokines 
and chemokines (94). Secreted cytokines trigger further inflammatory signaling in liver 
cells, the effects of which depend on the cell type. Kupffer cells will increase cytokine 
production creating a feed-forward effect. Hepatic stellate cells will enter into their 
activated stated where proliferation and collagen synthesis is increased, leading to 
fibrosis. In hepatocytes, cytokines can promote lipid accumulation and apoptosis. 
Importantly, hepatocyte apoptotic bodies and damage-associated molecular pattern 
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molecules (DAMPs) will further trigger inflammatory signaling in the surrounding cells. 
Chemokines promote the recruitment circulating immune cells so in the context of 
NASH, chemokines with increase the hepatic infiltration of immune cells (80, 94, 95). 
1.6.4 Inflammatory signaling pathways 
The many stimuli described in the previous section can trigger intracellular signaling 
pathways within hepatocytes, Kupffer cells, and other liver cell types which can further 
elevate the liver’s inflammatory status. These pathways are sensitive to the various 
stimuli implicated in NAFLD and NASH (lipotoxicity, ER and oxidative stress, cytokine 
signaling, etc.) and govern stimuli responses (apoptosis, cytokine production, etc.). The 
primary molecular pathways that will be discussed here are mitogen-activated protein 
kinase (MAPK) and nuclear factor-κB (NF-κB). 
1.6.4.1 MAPK pathways 
The MAPK pathways are integral to a large number of cellular processes due to the vast 
number of signals they detect, and responses they elicit. The MAPK proteins represent a 
family of serine and threonine kinases which are often described according to one of 
three subgroups: extracellular signal-regulated kinases (ERKs), c-Jun N–terminal kinases 
(JNKs), and p38 MAPKs. Each subgroup contains multiple isoforms, as shown in Figure 
1-5.  
MAPK stimuli include hormones, growth factors, cytokines, DAMPs, pattern associated 
molecular pattern molecules (PAMPs), and environmental stress. They are activated by 
upstream MAPK kinase (MAP2K) phosphorylation of conserved threonine/tyrosine 
residues, which follows prior activation by MAPK kinase kinases (MAP3Ks). This three 
tier kinase hierarchy represents what is be the classic model of MAPK signaling. The 
numerous functions of MAPK signaling will not be discussed in detail but how the ERK, 
JNK, and p38 pathways pertain to inflammation and metabolic dysfunction will be 
briefly described below. 
The ERK proteins were the first MAPKs to be described and exist in two isoforms, ERK1 
and ERK2. As their name suggests, they were originally found to have a role in mitogen 
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signaling including some of the mitogenic effects of insulin. In addition to their key role 
in growth and differentiation, ERKs have since been found to play a role in innate 
immunity and inflammation. The JNK proteins exist in three isoforms, JNK1/2/3 and 
were discovered for their ability to phosphorylate the c-Jun transcription factor, 
regulating the function of the activating protein 1 (AP1) family of transcription factors. 
Compared to ERK1/2, JNK1/2/3 is much more sensitive to environmental stresses and 
proinflammatory signaling. Lastly, the p38 MAPKs exist as α, β, γ, and δ isoforms and 
like the JNKs, have a greater sensitivity to stress and inflammatory signaling. 
Collectively, the MAPKs pathways respond to inflammatory stimuli and environment 
stresses to augment insulin sensitivity and inflammatory responses. Insulin sensitivity is 
reduced by IRS-1 serine phosphorylation by MAPKs (see section 1.5.3). Inflammatory 
responses are augmented though transcriptional regulation via AP1 heterodimers. 
Specifically, AP1 dimers can consist of a number of combinations of proteins such as 
ATF2, ELK1, SAP1a, c-Jun, and c-Fos. These dimer combinations determine the 
promoter targets of AP1, allowing AP1 to regulate a number of processes such as 
proinflammatory gene expression. MAPKs can phosphorylate these proteins, altering 
their activity or dimer stability (Figure 1-5) (96, 97). 
1.6.4.2 NF-κB pathway 
The NF-κB pathway transcriptionally regulates anti-apoptotic and proinflammatory 
processes. Most notably, active NF-κB directly increases the cytokine and chemokine 
gene expression. Extracellular signals such as cytokines, PAMPs, and DAMPs bind to 
cell surface receptors including toll-like receptors (TLRs) and tumor necrosis factor 
receptors (TNFRs). Signaling through these receptors can activate MAPK and NF-κB 
pathways. NF-κB is normally sequestered within the cytoplasm by inhibitor of NF-κB-α 
(IκBα) where it is unable to bind the promoters of target genes. Inflammatory signals 
from TLRs or TNFRs activate the inhibitor of IκBα kinase (IKK) complex, consisting of 
α, β, and γ subunits. Activation of IKKβ through phosphorylation leads to it 
phosphorylating IκBα. Phosphorylated IκBα leads to its ubiquitination and degradation, 
thus releasing NF-κB which can migrate to the nucleus and promote inflammatory gene 
expression (98, 99) (Figure 1-5).  
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Figure 1-5 General overview of inflammatory signaling pathways 
Intracellular signaling pathways activated in response to different types of inflammatory 
stimuli. Extracellular stimuli can include cytokines such as tumor necrosis factor α 
(TNFα), interleukin 1β (Il-1β), pathogen associated molecular patterns (PAMPs) such as 
lipopolysaccharide (LPS) and foreign DNA, damage associated molecular patterns 
(DAMPs) such as oxidized LDL (oxLDL) and ATP, free fatty acids (FFAs), and various 
growth factors. Receptors for these stimuli include the IL-1β receptor (IL-1βR), TNF 
receptor (TNFR), and toll-like receptor (TLR) families. Intracellular inflammatory 
stimuli and damage includes FFAs, diacylglyceride (DAG), ceramides, reactive oxygen 
species (ROS), endoplasmic reticulum (ER) stress, and ultraviolet (UV) light. Both 
intracellular stimuli and extracellular-receptor mediated stimuli can activate the mitogen 
activated protein kinase (MAPK) pathways. The MAPK pathways are activated at the 
levels of the MAPK kinase kinases (MAP3Ks) which activate the MAPK kinases 
(MAP2Ks) by serine/threonine phosphorylation. MAP2Ks activate the MAPK proteins 
by threonine/tyrosine phosphorylation. These include three main families: p38 MAPKs, 
c-Jun N–terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs). 
When activated these can regulate many transcription factors by serine/threonine 
phosphorylation. These factors form activating protein 1 (AP1) heterodimers (such as 
Jun-Jun, Jun-Fos, and Jun-ATF) which can regulate inflammatory gene expression. 
Activated MAPKs can also phosphorylate the insulin receptor substrate (IRS) at serine 
residues, leading to decreased activity and insulin resistance. Another major pathway is 
through the nuclear factor-κB (NF-κB) transcription factor, which is normally bound to 
inhibitor of NF-κB-α (IκBα) and sequestered in the cytosol. The inhibitor of IκBα kinase 
(IKK) family phosphorylates IκBα, causing its ubiquitination and degradation, releasing 
NF-κB, allowing it to translocate to the nucleus and regulate inflammatory gene 
expression. Figure created using references (80, 96–114). 
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1.7 Modulating Lipoprotein Metabolism - Current and 
Potential Drug Targets  
Efforts to lessen the onset of atherosclerotic CVD have primarily led to the development 
of therapies to lower LDL-C levels. An understanding of the molecular pathways that 
determine how the body maintains lipid homeostasis has offered clues as to how these 
pathways can be manipulated for therapeutic benefit. Indeed, this has allowed for target-
based drug design to develop several different therapies – some very successful while 
others not, and still many more whose clinical potential have yet to be determined. 
1.7.1 HMG-CoA reductase  
As mentioned in section 1.4.1, HMGCR catalyzes the conversion on HMG-CoA to 
mevalonate, the rate-limiting step of cholesterol biosynthesis. Statins inhibit hepatic 
HMGCR and thus decrease the intracellular concentrations of cholesterol. This results in 
the activation of the sterol-sensing SREBP-2, which upregulates genes involved in 
cholesterol synthesis and uptake such as HMGCR, PCSK9, and most importantly LDLR. 
The increase in membrane expression of the LDLR enhances the clearance of apoB100-
containing lipoproteins and thus lowers plasma LDL-C levels (52, 115). Clinically, 
statins have demonstrated robust efficacy in preventing CVD and death in several large 
cardiovascular outcomes trials and thus are currently the standard of care (8, 10, 116). 
1.7.2 Proprotein convertase subtilisin/kexin-9 
Proprotein convertase subtilisin/kexin 9 (PCSK9) has gone from its initial discovery to 
late stage clinical development all in the last 15 years (117). It was first identified in 
patients who inherited a gain-of-function mutation resulting in hypercholesterolemia and 
a reduction in LDLR expression (118). Conversely, it was also shown that patients with 
loss-of-function mutations had much lower LDL-C and showed protection from CVD 
(119). The PCSK9 protein is secreted predominantly from hepatocytes into the 
circulation, where is binds to the LDLR. When the LDLR is internalized while bound to 
PCSK9, it is degraded instead of being recycled back to the cell membrane surface. 
Therefore, total LDLR expression is decreased causing an increase in circulating LDL-C 
(120, 121) Since its discovery, monoclonal antibodies have been developed against the 
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PCSK9 protein which have been shown to be very effective in lowering LDL-C, even as 
much as 60% (122). Interestingly, statins are known to induce SREBP2 activation 
causing an increase in PCSK9 and LDLR expression, where inhibition of the latter with 
the former likely serving as a negative feedback mechanism. Therefore, PCSK9 
inhibition could negate this effect of increased PCSK9 expression and thus work 
synergistically in combination with statins to further increase hepatic LDLR expression 
and lower LDL-C (117, 121). Large cardiovascular outcomes trials are currently 
underway to test if PCSK9 inhibition can protect against CVD. 
1.7.3 Niemann-Pick C1-like protein 1  
Dietary and biliary cholesterol absorption in the gut takes place at the brush border of 
small intestinal cells.  Mediating this process is the enterocyte membrane protein 
Niemann-Pick C1-like protein 1 (NPC1L1) (123). Ezetimibe inhibits NPC1L1 and thus 
reduces intestinal cholesterol absorption and transport to the liver. In the liver this results 
in increased LDLR expression, a mechanism similar to that of statins. Ezetimibe as 
monotherapy does not lower LDL-C as much as a statin, however it can further lower 
LDL-C when used as an add-on to statin therapy (124). Ezetimibe has been in use for 
some time but whether its incremental benefit in LDL-C lowering as a combination 
therapy translates into improved cardiovascular outcomes was not known until recently. 
Compared to simvastatin monotherapy, ezetimibe plus simvastatin gave a small but 
significant reduction in LDL-C and improved cardiovascular outcomes (125). 
1.7.4 Cholesterol ester transfer protein 
As mentioned in section 1.3.4, CETP facilitates the transfer of CE from HDL to TRLs in 
exchange for TG. Preventing this exchange results in an elevation in HDL-C while also 
lowering LDL-C, so several efforts have been made to therapeutically inhibit CETP. The 
first of these attempts was with Pfizer’s torcetrapib, which indeed did increase HDL-C 
while also lowering LDL-C in up to Phase III clinical trials. However, in late 2006 Pfizer 
announced that it was terminating all further development of torcetrapib and in 2007 it 
was revealed that torcetrapib increased CVD events by 25% compared to placebo (126). 
This effect was attributed to an increase in blood pressure caused by torcetrapib and not a 
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result of CETP inhibition, per se (127). It was still an open question whether the so-called 
“HDL hypothesis” (raising HDL-C) was still valid and specifically if CETP inhibition 
could still be viable for the prevention of CVD. Further development of three other CETP 
inhibitors continued after confirming the absences of any effects on blood pressure (128). 
In 2012 Hoffmann-La Roche halted development of dalcetrapib (129) and in 2015 Eli 
Lilly did the same with evacetrapib (130) both citing futility due to a lack of efficacy in 
preventing CVD. This leaves Merck’s anacetrapib as the remaining CETP inhibitor still 
in late stage clinical development (131) although there is a lack of consensus about 
whether it should or will remain so (132, 133). 
These disappointing clinical findings have led to investigators taking a closer look at the 
evidence for CETP inhibition. Strong genetic evidence exists for loss of function variants 
resulting in increased HDL-C. However, it is still not known if HDL concentrations play 
a causal role in CVD development or if it is just a risk marker, and if raising HDL-C via 
CETP inhibition translates into CVD protection (133). Early studies showed that CETP 
gene transfer in mice increased atherosclerosis (134, 135) while CETP inhibition in 
rabbits was atheroprotective (136–138). However, other studies have found the opposite 
to be true (139, 140). In light of the inconsistencies in the animal studies it is important to 
note that mice do not express CETP and studies where mice express transgenic human 
CETP are unlikely to be representative of normal human metabolism. Additional studies 
have looked at plasma CETP function and concentration and its relationship with CVD 
risk. The six prospective studies that have looked at this have all showed an inverse 
relationship between CVD incidence and CETP activity (141–146). So if low CETP 
activity actually increases cardiovascular risk, it is hard to see the rationale for continued 
development of CETP inhibitors and has led some to argue that continuing clinical trials 
poses a risk to patients (147, 148). 
1.7.5 AMP-activated protein kinase  
AMP-activated protein kinase (AMPK) is a cell-autonomous sensor of cellular energy 
status and regulator of metabolic homeostasis. It is a highly conserved heterotrimeric 
serine/threonine kinase. Each heterotrimer consists of an α catalytic subunit, β scaffolding 
subunit, and γ regulatory subunit, with multiple isoforms existing for each (α1, α2, β1, 
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β2, γ1, γ2, γ3). These isoforms allow for the formation of up to 12 potential 
heterotrimers, and expression patterns differ in a tissue and species dependent manner. 
For example, α1β2γ1and α2β2γ1 are the predominant isoforms in human liver and 
muscle, respectively, while α2β1γ1 predominates in rat liver (149, 150). AMPK is 
acutely sensitive to changes in intracellular energy status due to its ability to detect 
changes in AMP:ADP:ATP ratios. In response to low intracellular energy status under 
conditions such as hypoxia or nutrient deprivation, AMPK is activated by threonine-172 
phosphorylation of the α subunit along with AMP binding to the γ subunit. Active AMPK 
phosphorylates a myriad of targets, triggering several metabolic responses (Figure 1-6).  
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Figure 1-6 Hepatic AMPK targets 
Activated AMPK phosphorylates many targets to regulate cellular energy balance. 
Activated catabolic processes include autophagy, mitochondrial biogenesis, and fatty acid 
β-oxidation. Inhibited anabolic processes include cholesterol synthesis, fatty acid 
synthesis, protein synthesis, and gluconeogenesis. ACC, acetyl-CoA carboxylase; CRCT, 
cAMP response element binding protein-regulated transcription coactivator; HMGCR, 3-
hydroxy-3-methylglutaryl-CoA reductase; mTORC1, mammalian target of rapamycin 
complex 1; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1-α; 
RAPTOR, regulatory associated protein of mTOR; SREBP, sterol regulatory element 
binding protein; TSC, tubular sclerosis complex; ULK, unc-5 like kinase. 
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Ultimately, AMPK signaling augments cellular metabolism towards catabolic, ATP-
producing pathways, while concomitantly inhibiting non-essential anabolic, ATP-
consuming pathways. Therefore, AMPK activation can promotes processes such as fatty 
acid β-oxidation and glycolysis while suppressing fatty acid synthesis and 
gluconeogenesis, making it a compelling target for treating conditions relating to 
cardiovascular disease, diabetes, inflammation, and even cancer (151–153). However, 
there are no therapies currently in clinical use that directly target AMPK. There is 
evidence that AMPK plays a role in the mechanism of action of several widely used 
drugs such as the aspirin metabolite salicylate (154–156) and metformin (157–160). 
Of the many targets of AMPK, the most notable is possibly acetyl-CoA carboxylase 
(ACC) due to is key roles in fatty acid synthesis and β-oxidation (sections 1.4.2 and 
1.4.4, respectively). Specifically, AMPK phosphorylation of ACC reduces its ability to 
produce malonyl-CoA, thus providing less substrate for fatty acid synthesis while also 
relieving inhibition on fatty acid β-oxidation. Malonyl-CoA inhibits Cpt1α and β-
oxidation, and decreases in malonyl CoA relives this inhibition. Another target is 
HMGCR, which like ACC is also inhibited by AMPK phosphorylation. However, 
although these two proteins were the first discovered targets of AMPK (161, 162), there 
is still very little understanding of the physiological relevance of HMGCR inhibition by 
AMPK phosphorylation (163). The duel inhibition of ACC and HMGCR by AMPK 
likely explains its ability to limit both fatty and cholesterol synthesis, respectively. 
1.7.6 ATP-citrate lyase  
ATP-citrate lyase (ACL) is responsible for the synthesis of cytosolic acetyl-CoA, a 
central metabolite in many metabolic pathways. It utilizes cytosolic citrate, CoASH, and 
ATP to generate acetyl-CoA plus oxaloacetate. Cytosolic citrate can come from transport 
out of the mitochondria, since it as a citric acid cycle intermediate, or can be synthesized 
within the cytosol from glutamate. As mentioned in section 1.4, cytosolic acetyl-CoA is a 
substrate for both fatty acid and cholesterol synthesis (Figure 1-7). This has been 
demonstrated with ACL knockout models and inhibitors resulting in suppressed de novo 
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fatty acid and cholesterol synthesis. Additionally, ACL can be nutritionally regulated by 
two mechanisms. First, it’s gene is an SREBP target and so it is upregulated in response 
to insulin. Second, it has been shown to be phosphorylated and activated by AKT (164–
168).  
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Figure 1-7 Mitochondrial and cytosolic acetyl-CoA as both a substrate and product 
Hepatic acetyl-CoA exists in multiple intracellular pools. The mitochondrial and nucleo-
cytosolic pools are the most significant but there does exist peroxisomal and intrareticular 
pools as well (not shown). Mitochondrial acetyl-CoA can be derived from many sources 
including pyruvate (from glycolysis), free fatty acids (from β-oxidation), and amino acid 
metabolism. The majority of this mitochondrial acetyl-CoA is metabolized in the 
tricarboxylic acid (TCA) cycle or used for ketone body synthesis. To migrate between the 
mitochondrial and nucleo-cytosolic pools, acetyl-CoA must either be converted to citrate 
or utilize the carnitinepalmitoyl transferase system (not shown). Most cytoplasmic acetyl-
CoA is synthesized from citrate by ATP-citrate lyase but can also be synthesized from 
acetate by acyl-CoA synthetase. The nucleo-cytosolic pool can be used for the synthesis 
of fatty acids or cholesterol or for protein acetylation. Acetyl-CoA carboxylase (ACC) 
catalyzes the conversion of acetyl-CoA to malonyl-CoA which is used by fatty acid 
synthase (FAS) to generate acyl-CoAs. Acetyl-CoA acetyltransferase creates acetoacetyl-
CoA which is converted by 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS) to 
generate HMG-CoA for cholesterol synthesis. 
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1.7.6.1 Bempedoic acid 
Bempedoic acid (BA; also known as ETC-1002 or 8-hydroxy-2,2,14,14-
tetramethylpentadecanedioic acid) is an ACL inhibitor in clinical development for the 
treatment of hypercholesterolemia. It resembles a fatty acid analogue and was identified 
in a drug screen for its ability to inhibit cholesterol and fatty acid synthesis in vivo (169). 
Results from up to Phase IIb clinical trials have consistently shown a 30% lowering of 
LDL-C in hypercholesterolemic patients and an unanticipated 40% lowering in high 
sensitivity C-reactive protein (hsCRP) with BA monotherapy (168, 170). To date clinical 
studies have been completed in over 1000 subjects with more than 700 receiving BA 
across 10 clinical trials (3 Phase I, 7 Phase II). The majority of patients studied had 
hypercholesterolemia but BA has also been studied in patients with Type 2 Diabetes, 
statin intolerance, hypertension, or on stable statin or ezetimibe therapy (171–176). There 
is evidence in rodent models that BA may improve metabolic dysregulation associated 
with the metabolic syndrome, including insulin resistance, hepatic steatosis, atherogenic 
dyslipidemia and tissue inflammation (177–179).  
BA appears to target the liver, where it inhibits ACL and may also activate AMPK 
(Figure 1-8) (177). To inhibit ACL, BA must be formed into a coenzyme-A thioester by 
acyl-CoA synthase (ACS). It was recently shown that the specific ACS isoform that 
catalyzes BA-CoA formation has high expression in human liver while showing no 
expression in muscle, explaining how BA’s mechanism is liver-specific (180). BA-CoA 
binds to and inhibits ACL in a manner competitive for coenzyme-A, resulting in a rapid 
decrease in acetyl-CoA and HMG-CoA while raising cytosolic citrate both in vitro and in 
vivo (168, 177). Activation of AMPK by BA phosphorylates and inhibits ACC and 
HMG-CoA reductase likely contributing to the observed inhibition of fatty acid synthesis 
and cholesterol synthesis, respectively, both in vitro and in vivo (Figure 1-6). Inhibition 
of ACC depletes the malonyl-CoA pool for fatty acid synthesis by FAS and relieves the 
inhibition of CPT1α-mediated β-oxidation by malonyl-CoA. Increased β-oxidation was 
observed in primary rat hepatocytes and in vivo results demonstrated increased plasma β-
hydroxybutyrate, suggesting increased hepatic β-oxidation (168, 169).   
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Figure 1-8 Hepatic effects of bempedoic acid. 
Bempedoic acid (BA) must first to converted to a CoA thioester (BA-CoA) to inhibit 
ATP-citrate lyase (ACL). This reduces cytosolic acetyl-CoA providing less substrate for 
sterol and fatty acid synthesis. BA can also activate AMPK by threonine phosphorylation 
of the α subunit. This results in the reduction of ACC activity and thus malonyl-CoA 
synthesis. As a result, fatty acid synthesis is reduced and β-oxidation is increased. 
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Studies in mice, rats, and hamsters have shown that BA increases hepatic protein 
expression of peroxisome proliferator activated receptor (PPAR) γ-coactivator 1α 
(PGC1α), a regulator of mitochondrial biogenesis, and elevates plasma levels of β-
hydroxybutyrate (168). This occurred while also decreasing plasma cholesterol, TG, 
glucose and insulin, as well as hepatic fat content, fatty acid synthesis, and cholesterol 
synthesis (169, 177, 178, 181). In cultured human macrophages and murine adipose 
tissue, BA down-regulated proinflammatory MAPK signaling pathways and decreases 
cytokine and chemokine secretion through activation of AMPK signaling (178). The 
effect that BA has on atherosclerotic lesion development in Ldlr-/- mice fed a high-fat, 
cholesterol-containing diet, remains to be elucidated.  
1.8 Model to be used  
Mouse models are very common for studying several of the abnormalities associated with 
the metabolic syndrome. The C57BL/6 mouse is by far the most utilized strain due to its 
increased susceptibility to metabolic diseases when compared to other inbred strains of 
mice (182, 183). Using the C57BL/6 background, knockout of the LDLR gene (Ldlr) 
results in some susceptibility to atherosclerosis when fed a low fat chow diet, but plaques 
usually do not develop beyond small fatty streaks. Ldlr
-/-
 mice fed a high fat, cholesterol 
containing diet however, develop far more severe atherosclerotic lesions over a 
reasonably short period of time due to the large increase in plasma cholesterol 
concentrations. These lesions are usually characterized as being large lipid-rich and foam 
cell-predominant and readily develop in the aortic sinus and aorta. This is a widely used 
model for studying atherosclerosis (184, 185). Additionally, this mouse models exhibits 
obesity, dyslipidemia, NAFLD development and inflammation when fed a diet with 
added fat and cholesterol (186–189). 
1.9 Hypothesis and Scope of Thesis  
In the current study, the ability of BA to protect against CVD through the prevention of 
CVD-associated risk factors was investigated. Specifically, using a murine model of the 
metabolic syndrome and atherosclerosis, this work sought to determine if targeting 
hepatic ACL and AMPK with BA could prevent the onset of abnormalities associated the 
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metabolic syndrome such as increased adiposity, insulin resistance, dyslipidemia, hepatic 
steatosis, inflammation and atherosclerosis. These abnormalities are linked to the process 
of atherogenesis. Therefore, the hypothesis to be tested was that in Ldlr-/- mice fed an 
atherogenic diet high in fat and cholesterol, BA treatment would prevent the onset of 
obesity, dyslipidemia, hepatic steatosis, and insulin resistance, attenuate inflammation, 
and thus prevent the development of atherosclerosis.  
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Chapter 2  
2 Methods 
2.1 Animals and diets 
Male, 8-week old Ldlr-/- C57BL/6 mice (B6.129S7-Ldlrtm1Her/J; Stock# 002207, 
Jackson Laboratory, Bar Harbour, ME) were maintained at 23°C on a 12-hour dark/light 
cycle and cared for in accordance with the Canadian Guide for the Care and Use of 
Laboratory Animals. All experimental procedures were approved by the Animal Care 
Committee at the University of Western Ontario (protocol number: 2012-028). 120 mice 
(n = 24/group) were fed ad libitum either control diets or diets supplemented with 
Bempedoic acid (BA, also known as ETC-1002; Ricerca Biosciences, Concord, OH) for 
12 weeks. Diet compositions are shown on Table 2-1. Five groups of mice (see Figure 
2.1) received either a purified rodent chow control diet (14% of calories from fat, Harlan 
Teklad T8604, Madison, WI), a high-fat cholesterol-containing diet (HFHC; 42% 
calories from fat and 0.2% cholesterol, Harlan Teklad TD09268) or HFHC supplemented 
with approximately 3, 10 or 30 mg of BA per kg body weight per day (mg/kg BA). BA 
was solubilized in ethanol and mixed with HFHC at the appropriate dose, followed by air 
drying of ethanol. Fresh food was provided twice per week with updated BA doses, 
which were based on the caloric intake and body weight measurements determined the 
previous day. Daily caloric intake was measured as the difference between the mass of 
food provided minus the mass of food remaining, which was then divided by change in 
time and multiplied by the caloric density of the food (chow = 3.1 kcal/g, HFHC = 4.5 
kcal/gram).  
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Table 2-1: Mouse diets 
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Figure 2-1 Study design 
Bloods samples were taken at baseline and weeks 4, 8, and 12. Metabolic cage 
experiments were performed at week 9. Micro (μ) CT scans were performed at week 10. 
Glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed at week 11. 
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2.2 Blood and tissue collection  
All mice were fasted 6 hours before sacrifice or blood collection. Blood was collected at 
baseline and weeks 4, and 8 via a small nick in the tail vein at which time blood glucose 
was measured by glucometer (Bayer Contour Blood Glucose Monitoring System, Bayer 
Healthcare, Mississauga, ON). At sacrifice, mice were anesthetized with ketamine-
xylazine (100 μg/g Ketamine Hydrochloride: Bioniche Animal Health Canada Inc.  
Belleville ON and 10 μg/g Xylazine: Bayer Healthcare, Animal Health Division, Bayer 
Inc. Toronto ON) and tissue dissections were performed via midline incision. A small 
section of liver tissue was harvested first by freeze-clamping, using pliers chilled in liquid 
nitrogen (190). Blood was collected in EDTA syringes by cardiac puncture, and plasma 
collected after centrifugation at 12 000 RPM at 4°C. Plasma samples were stored at -
20
o
C. Epididymal adipose tissue, remaining liver, heart and aorta where then dissected 
and cleaned. For histological analyses, samples of liver and heart (containing the aortic 
root) were placed in Optimum Cutting Temperature (OCT) Compound (Sakura Finetek, 
USA Inc. Torrance, CA USA), frozen on dry ice and stored at -80
o
C. Remaining tissues 
were snap-frozen in liquid nitrogen and stored at -80°C. 
2.3 Plasma analyses  
Plasma was analyzed for cholesterol (Wako, VWR, Mississauga, ON) and TG (Roche 
TG/GB, glycerol blanked, Roche Diagnostics, Laval QC) concentrations by enzymatic 
assays as described previously (191). Concentrations of insulin (ALPCO Diagnostics, 
Windham, NH) and serum amyloid-A (SAA) (Invitrogen, Life Technologies, 
Mississauga, ON) were determined by mouse specific ELISA as per manufacturer’s 
instructions. Fast performance liquid chromatography (FPLC) was performed on fresh 
EDTA-plasma using an AKTA purifier and a Superose 6 column as previously described 
(191). FPLC separates plasma contents on the basis of size, thus allowing for the 
separation and identification of the lipoproteins present in a sample. Cholesterol and TG 
measurements were performed on samples from each eluted fraction as described above. 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were analyzed 
using enzymatic kinetic rate reactions (Roche Diagnostics) performed at the London 
Health Sciences Centre Core Laboratory. 
51 
 
2.4 Glucose and insulin tolerance tests 
Glucose and insulin tolerance testing were performed after 11 weeks on diet, to measure 
glucose disposal and insulin sensitivity, respectively. For glucose tolerance tests (GTTs), 
mice were fasted for 6 hours prior to receiving 1g/kg glucose by i.p. injection of a 15% 
glucose, 0.9% NaCl solution. For insulin tolerance tests (ITTs), mice were fasted for 5 
hours prior to injection of 0.6 IU/kg Novolin ge Toronto (Novo Nordisk) i.p. Blood 
glucose measurements by glucometer were determined on samples taken up to 120 
minutes (GTT) or 60 minutes (ITT) post-injection and reported as blood glucose vs time 
or glucose change from baseline vs time. 
2.5 Metabolic analyses 
Oxygen consumption (VO2, L/kg/hour), carbon dioxide production (VCO2, L/kg/hour), 
and respiratory exchange ratio (RER, VCO2/VO2) were measured using the 
Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus 
Instruments, Columbus, OH). Mice had continuous access to food and water and after a 
24-hour acclimatization period data was collected for up 48 hours. 
For fatty acid oxidation, fresh liver was homogenized in 0.1 M phosphate buffer 
containing 0.25 M sucrose and 1 mM EDTA. Liver homogenates were incubated for 30 
min at 37ºC in a buffer containing 150 mM KCl, 10 mM Hepes (pH 7.2), 5 mM Tris 
malonate, 10 mM MgCl2, 1 mM carnitine, 0.15% Fatty-Acid Free Bovine Serum 
Albumen (Sigma Aldrich, Oakville, ON), 5 mM ATP and 50 µM (µCi) 
3
H-palmitate 
(Perkin Elmer, Waltham, MA) complexed with FAF-BSA. Reactions were stopped with 
200 µL 0.6 N perchloric acid and unreacted fatty acids extracted with n-hexane.
 3
H2O in 
the aqueous phase was measured by liquid scintillation counting (191).  
Fatty acid and cholesterol synthesis were measured following i.p. injection of 
radiolabeled acetic acid (Amersham Canada Ltd). Briefly, mice fasted for 6 hours were 
injected with 20 µCi of [1-
14
C]-acetic acid and sacrificed 1 hour later. Tissues (500 mg) 
were extracted in chloroform:methanol and incorporation of [1-
14
C]-acetic acid into fatty 
acid and cholesterol were assayed as described previously (191). 
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2.6 Micro-computed tomography imaging 
Whole-mouse composition analysis was done by micro-computed tomography (μCT) 
imaging using a Locus Ultra μCT scanner (GE Healthcare, London, ON) after mice were 
on diet for 10 weeks. Total adipose volume was measured using MicroView 2.2 with 
threshold values of -380 to -30 Hounsfield Units to identify adipose tissue (192, 193).  
2.7 Tissue sectioning and histology 
Tissue histological and morphological analysis were performed using hearts or liver 
frozen in OCT and stored at -80°C (194, 195). Frozen serial sections were prepared with 
a Leica CM 3050S cryostat to cut 10 and 8 μm thick sections for heart and liver, 
respectively. Slides were stained with hematoxylin and Eosin (H&E), oil red-O (ORO, 
Sigma Aldrich, Oakville, ON), or picrosirius red. Adjacent slides were analyzed by 
immunohistochemistry (IHC) for CD68, cleaved caspase 3 (CC3), or smooth-muscle α-
actin (SMA) as described previously (195), see Table 2-2 for antibody information. 
Briefly, slides were fixed in acetone followed by air drying, rehydrating in phosphate 
buffered saline (PBS) and blocking with 2% Fatty-Acid Free Bovine Serum Albumin  
(Sigma Aldrich, Oakville, ON) in PBS. Primary (Table 2-2) and biotinylated secondary 
(Table 2-3) antibody incubations were performed in blocking solution. Peroxidase 
blocking with 3% hydrogen peroxide was followed by incubation with the ABC reagent 
(ABC Elite Standard Kit, Vector Laboratories, Burlington, ON). Slides were exposed to 
the DAB substrate (Peroxidase substrate kit, Vector Laboratories) and counterstained in 
hematoxylin (Sigma-Aldrich). 
Within atherosclerotic lesions, areas positive for ORO, CD68 and SMA were measured 
with ImageJ 1.50 (National Institutes of Health) and expressed as percent of total lesion 
area. Areas positive for picrosirius red were measured with ImageJ using MRI Fibrosis 
Tool (196) and expressed as percent of total lesion area. Lesion CC3-positive nuclei and 
total nuclei were counted with ImageJ using Color Deconvolution (197, 198) and 
expressed as percent CC3 positive nuclei.  
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2.8 Tissue lipid analysis 
Liver and aortic tissues were weighed and lipids extracted using the chloroform:methanol 
(2:1) method of Folch, et al (199). Following extraction, samples and standards were 
dried under N2 gas and solubilized in chloroform with 1% Triton X-100. Following 
drying under N2 gas again, samples were resolubilized in water and levels of 
triacylglycerol (TG), total cholesterol (TC) and free cholesterol (FC) were measured by 
enzymatic assay. Lipid measurements were normalized to wet tissue weight. Cholesteryl 
ester (CE) was determined by the difference between TC minus FC (194). 
2.9 Tissue gene expression 
Quantitative real-time PCR (qRT-PCR) was performed on RNA isolated from liver or 
aorta using TRIzol® (Life Technologies, Burlington, ON). Reverse transcription into 
cDNA was performed using the High Capacity Reverse Transcription kit (Applied 
Biosystems, ABI). All primer and probe sets were from Applied Biosystems (Streetsville, 
CA) except Srebf1c (200). The probe and primer sequences for Srebf1c were designed 
using Primer Express 2.0 (ABI). Primers were obtained from Sigma-Genosys (Forward 
Primer: CAGGCCCGGGAAGTCACT; Reverse Primer: 
GACCACGGAGCCATGGATT) and the probes from ABI (Probe: FAM-
ATTTGAAGACATGCTCCA-MG). All qRT-PCR assays were previously optimized and 
known to work for murine liver and aortic tissues. 
2.10 Tissue protein expression 
Frozen full-length aorta or freeze clamped liver samples (~50mg) were homogenized as 
previously described (195). Proteins were separated on 4-15% acrylamide gels (Bio-Rad) 
by SDS-PAGE and transferred to Immobilon-FL (EMD Millipore, Darmstadt, Germany) 
PVDF membranes. Primary antibodies were used for phosphorylated and total AMPK, 
ACC, ERK1/2, p38, JNK1/2, IKKαβ, and IκBα along with β-actin. Detailed information 
of primary antibodies is shown in Table 2-2. Phosphoproteins were analyzed using both 
phospho-specific and total antibodies on the same blot, with antibodies raised in different 
species (rabbit, mouse, or goat). Appropriate secondary antibodies (Table 2-3) conjugated 
to fluorophores of different emission wavelengths (IRdye-800CW or IRdye680RD, LI-
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COR Biosciences, Lincoln, NE) were multiplexed to allow for simultaneous detection of 
phosphorylated and total proteins. A LI-COR Odyssey Fc scanner (LI-COR Biosciences) 
was used to detect the near-infrared emission signals (700 and 800 nm wavelength) 
produced after laser excitation of the conjugated fluorophores. Image Studio 5.0 (LI-COR 
Biosciences, Lincoln, NE) was used for signal quantitation. Phosphoproteins were 
normalized to loading control (total protein of interest) and expressed as fold change 
compared to chow-fed mice. Β-actin was also probes for each blot a visual determination 
of equal loading. Blots were optimized to ensure signal was in a linear range. 
2.11 Statistical analyses 
All data are expressed as means +/- SEM. Statistical analyses were performed using 
GraphPad Prism 6. A One-way ANOVA was used to test for differences between groups 
of three or more followed by Tukey’s post-hoc test. A two-tailed t-test was used to test 
for differences between two groups. A Two-way ANOVA was used to test for differences 
between groups when data was collected over a series of timepoints, followed by a 
Tukey’s post-hoc test. P < 0.05 was deemed statistically significant as represented by 
letters comparing three or more groups. 
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Table 2-2 Primary antibodies used for Western blotting and IHC 
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Table 2-3 Secondary antibodies used for Western blotting and IHC 
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Chapter 3  
3 Results 
3.1 Bempedoic acid attenuates the HFHC-induced 
elevation in body weight and adiposity    
Male, 8 week old Ldlr
-/-
 mice showed no differences in daily caloric intake between any 
groups fed HFHC ± BA for 12 weeks, while chow-fed mice had significantly lower 
caloric intake compared to all groups (Figure 3-1A). Any group receiving the HFHC diet 
showed a significantly increased gain in body weight when compared to chow-fed mice 
(Figure 3-1B). Compared to HFHC feeding alone, mice fed 3 and 10 mg/kg BA displayed 
no difference in body weight while mice treated with 30mg/kg BA had a significantly 
lower gain in body weight compared to mice fed HFHC (Figure 3-1BC). 30 mg/kg BA 
appeared to reduce body weight through a reduction in adiposity as epididymal fat pad 
mass measured at sacrifice was significantly less than HFHC alone while 3 and 10 mg/kg 
BA showed no change (Figure 3-1D). Additionally, μ-CT measurements of body 
composition after 10 weeks on diet showed an attenuation in whole body adiposity with 
30 mg/kg BA with no effect on lean or skeletal tissue mass (Figure 3-1E). 
3.2 Bempedoic acid prevents hyperlipidemia 
Plasma cholesterol and TG concentrations were elevated (5-fold and 4-fold, respectively) 
in mice fed the HFHC diet compared to mice fed chow. Hypercholesterolemia was 
significantly attenuated with both 10 and 30 mg/kg BA but not 3 mg/kg BA (Figure 3-
2A) and hypertriglyceridemia was significantly attenuated with all three doses of BA 
(Figure 3-2B). Cholesterol and TG concentrations in plasma lipoproteins separated by 
FPLC revealed that the HFHC diet greatly elevated the VLDL to LDL fractions 
compared to chow. Reductions in plasma lipids with 30 mg/kg BA took place primarily 
in the VLDL fractions with some effects observed on IDL, LDL, and HDL cholesterol 
fractions (Figure 3-3). 
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Figure 3-1: Effects of BA on body weight and adiposity. 
Average daily caloric intake based on grams of food over the course of the 12-week study 
(A) (n=22-24). Weekly body weight measurements taken throughout the 12-week study 
(B) (n=22-24). Change in body weight from baseline to week 12 (C) (n=22-24). 
Epididymal fat pad mass taken at sacrifice (D) (n=22-24). Total whole body adipose, 
lean, and skeletal tissue mass measured by micro-CT scanning (D) (n=8). Data are means 
± SEM, different letters indicate statistical differences by one-way (A, C-E) or two-way 
(B) ANOVA, P < 0.05. Statistical differences in (B) are for the whole curve. 
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Figure 3-2: Effects of BA on plasma lipids 
Plasma cholesterol (A) and triacylglycerol (B) concentrations from samples taken every 4 
weeks (n=12). Data are means ± SEM, different letters represent statistical differences of 
whole curves by two-way repeated measures ANOVA, P < 0.05. 
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Figure 3-3: FPLC analysis of the effects of BA on plasma lipids. 
Fast-performance liquid chromatography (FPLC) fractions from plasma collected after 12 
weeks on diet, analyzed for cholesterol (A) and triacylglycerol (B) concentrations (n=5-
12). Area under the curve (AUC) values for very low-density lipoprotein (VLDL) 
(fractions 5-9) and low-density lipoprotein (LDL) (fractions 10-19) analyzed by one-way 
ANOVA, P < 0.05. All data are means ± SEM. 
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3.3 Bempedoic acid prevents hepatic lipid 
accumulation 
The HFHC diet caused significant increases in hepatic TG, TC, FC, and CE compared to 
chow feeding alone. This effect was mirrored with the 3 mg/kg BA group which 
significantly elevated all measured lipids compared to chow-fed mice while showing no 
significant differences compared to the HFHC-fed group. TG, TC, FC, and CE were 
significantly lowered by both 10 and 30 mg/kg BA compared to HFHC. Interestingly, BA 
at 10 and 30 mg/kg showed no significant differences in liver lipid content compared to 
those in chow-fed mice (Figure 3-4A-D). These results were reflected in the liver 
histology when stained for neutral lipids with ORO (Figure 3-4E). 
3.4 Bempedoic acid influences multiple metabolic 
pathways in the liver 
It was observed that there was a dose-dependent increase in liver weight despite the large 
reductions in lipid content (Figure 3-5A). Plasma ALT and AST concentrations showed 
no significant changes between all groups suggesting normal liver function (Figure 3-
5BC). 
To further understand the mechanism of action of BA in the liver, analyses of gene and 
protein expression were carried out. BA has been previously demonstrated to activate the 
AMPK pathway in rodent liver (177). This was assessed in mice treated with 30 mg/kg 
BA by Western blotting for phosphorylation (p) of both AMPK and its target ACC. Both 
pAMPK and pACC were suppressed in the liver of HFHC-fed mice compared to mice 
fed chow. Treatment with 30 mg/kg BA reversed this effect resulting in significantly 
increased pAMPK and pACC relative to the HFHC diet alone (Figure 3-6). Additionally, 
compared to chow and 30 mg/kg BA, the HFHC diet unexpectedly appeared to increase 
total AMPK protein levels. This increase was not quantified and how this should be 
interpreted remains uncertain. 
Hepatic expression of genes involved in fatty acid β-oxidation were analyzed by qRT-
PCR. Ppara and its target genes, Cpt1a and Acox were generally increased with both 10 
and 30 mg/kg BA groups (Figure 3-7A). There was a particularly strong effect on Acox 
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expression, which is entirely regulated by PPARα activity (57). The HFHC diet induced a 
large elevation in the lipogenic transcription factor Srebf1c compared to the chow diet 
and this was significantly attenuated in 30 mg/kg BA-treated mice (Figure 3-7B). 
Interestingly, the hepatic expression of other lipogenic genes was generally increased 
with BA treatment compared to the HFHC diet alone. Specifically, when compared to 
livers from HFHC-fed mice alone, 30 mg/kg BA significantly increased the expression of 
Acacb and Fasn while trends were present for the remaining genes (Srebf2, Acaca, 
Hmgcr, and Pcsk9) with the exception of Acly (Figure 3-7B). This is possibly due to a 
compensatory feedback response resulting from inhibition of ACL, reduced intracellular 
sterols, and increased SREBP-2 activity. 
3.5 Bempedoic acid improves hepatic lipid metabolism 
Hepatic lipid metabolism was assessed biochemically by measuring rates of hepatic fatty 
acid β-oxidation and fatty acid synthesis. Compared to chow-fed mice, HFHC feeding 
resulted in a small nonsignificant reduction in β-oxidation of 3H-palmitic acid and a large 
significant increase in 
14
C-acetic acid incorporation into fatty acids (Figure 3-8AB). 30 
mg/kg BA significantly enhanced β-oxidation compared to chow and HFHC feeding 
while also significantly reducing fatty acid synthesis when compared to HFHC alone 
(Figure 3-8AB). These metabolic improvements are consistent with activated AMPK and 
reduced SREBP-1c gene expression. Metabolic cage experiments were performed to 
measure respiratory exchange ratio (RER, a measure of glucose versus lipid fuel 
utilization) and respiration rates (VO2 and VCO2). Chow-fed mice had a significantly 
higher RER during the dark cycle compared to the HFHC and 30 mg/kg BA groups. The 
high RER in the mice fed chow indicates a preference towards carbohydrate metabolism 
reflecting their carbohydrate-based diet. The lower RER values observed in the HFHC 
and 30 mg/kg BA mice were not different from one another and reflect the high lipid 
content in the diets of these groups. Respiration rates (VO2 and VCO2) displayed small 
trends towards reduced rates in HFHC-fed mice compared to the chow and 30 mg/kg BA 
groups but no changes were significant (Figure 3-8CD). This suggests that any potential 
differences in energy expenditure were not large enough to be detected.  
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Figure 3-4: Effects of BA on hepatic lipids. 
Liver free cholesterol (FC), cholesteryl ester (CE), total cholesterol (TC), and 
triacylglycerol (TG) (A-D) (n=14). Oil red-O (ORO) staining of liver tissue (E). Data are 
means ± SEM, different letters represent statistical differences by one-way ANOVA, P < 
0.05. 
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Figure 3-5: Effects of BA on liver size and function 
Liver mass measured at sacrifice (A) (n=24). Plasma ALT (B) and AST (C) values (n=8). 
Data are means ± SEM, different letters represent statistical differences by one-way 
ANOVA, P < 0.05. 
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Figure 3-6: Effects of BA on the AMPK signaling pathway. 
Representative immunoblots of biological replicates for phospho- and total AMPK and 
ACC (A) with quantitations by densitometry shown below (B) (n=7-8). Data are means ± 
SEM, different letters indicate statistical differences by one-way ANOVA, P < 0.05.  
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Figure 3-7: Hepatic effects of BA on metabolic gene expression. 
Hepatic gene expression of peroxisome-proliferator receptor alpha (Ppara) and its targets 
carnitinepalmitoyl transferase 1a (Cpt1a) and acyl-CoA oxidase (Acox) (A) and lipogenic 
genes sterol response element-binding protein (SREBP)-1c (Srebf1c), SREBP-2 (Srebf2), 
acetyl-CoA (ACC)-1 (Acaca), ACC-2 (Acacb), ATP-citrate lyase (Acly), fatty acid 
synthase (Fasn), 3-hydroxy-3-methylglutary-CoA reductase (Hmgcr), and proprotein 
convertase subtilisin/kexin type 9 (Pcsk9) (B) (n= 8-12). Data are means ± SEM, 
different letters indicate statistical differences by one-way ANOVA, P < 0.05. 
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Figure 3-8: Effects of BA on hepatic lipid metabolism. 
Hepatic β-oxidation (FAO) of 3H-palmitic acid into 3H2O (A) and hepatic fatty acid 
synthesis (FAS) measured by incorporation of 
14
C-acetic acid into 
14
C-fatty acids (B) 
(n=8). Metabolic cage measurements of light and dark cycle volume of oxygen consumed 
(VO2) and carbon dioxide produced (VCO2) (C), and respiratory exchange ration RER 
(D) (n=6-12). Data are means ± SEM, different letters represent statistical differences by 
one-way ANOVA P < 0.05. 
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3.6 Bempedoic acid prevents impaired glucose 
homeostasis 
Fasting blood glucose and plasma insulin were measured over the duration of the study at 
baseline and weeks 4, 8, and 12. By week 12, blood glucose for the chow-fed mice was 
significantly less than the HFHC-fed mice (Figure 3-9A). Mice treated with 30 mg/kg BA 
also showed a significant reduction in blood glucose compared to HFHC, while 3 and 10 
mg/kg BA had no effect (Figure 3-9A). Plasma insulin concentrations were significantly 
elevated in the HFHC and 3 mg/kg BA groups compared to chow fed mice, whereas 30 
mg/kg BA significantly attenuated plasma insulin to levels similar to those in chow-fed 
mice (Figure 3-9B). 
Glucose and insulin tolerance tests showed reduced glucose and insulin sensitivity in 
HFHC-fed mice compared to chow-fed mice. In mice treated with 10 and 30 mg/kg BA, 
glucose and insulin tolerance improved (Figure 3-10AB). However, when the data was 
expressed as the change from baseline these effects were lost (Figure 3-10CD). 
3.7 Bempedoic acid reduces inflammatory marker 
expression 
To examine the effects of BA on inflammation, gene and protein expression analyses 
were used to assess proinflammatory signaling pathways in liver and aortic tissue. The 
MAPK (p38, ERK, and JNK) and NFκB (IKK and IκBα) signaling cascades link the 
effects of inflammatory stimuli to a cellular response, usually through a transcriptional 
mechanism. These inflammatory pathways have been suggested to play a role in 
pathologies associated with the metabolic syndrome, such as insulin resistance. In liver, 
the HFHC diet had little influence in MAPK signaling compared to chow. Mice treated 
with 30 mg/kg BA showed significantly decreased phosphorylation of p38 and ERK1/2 
compared to both chow and HFHC alone (Figure 3-11). In the aorta, the HFHC diet 
significantly increased JNK phosphorylation compared to chow, an effect that was 
attenuated with 30 mg/kg BA (Figure 3-12). The remaining MAPKs showed minimal 
differences in phosphorylation between the chow, HFHC, and 30 mg/kg BA groups. 
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Phosphorylation of IKK and IκBα, regulators of NFκB activation, was minimal for all 
groups and also showed no differences (Figure 3-11, 3-12). 
Under inflammatory conditions, such as those seen with HFHC feeding, tissues will 
display an increase in classically activated macrophage (M1, proinflammatory) gene 
expression and lower alternatively activated macrophage (M2, reparative and anti-
inflammatory) gene expression. This was observed in the livers and aortae of HFHC-fed 
mice for several of the genes measured when compared to mice fed chow alone (Figure 
3-13A). In liver, this effect was attenuated with 30 mg/kg BA for all M1 genes measured 
and was statistically significant for Tnf and Ccl3 (Figure 3-13A). In aortic tissue of 
HFHC-fed mice, M1 gene expression was elevated. Treatment with both 10 and 30 
mg/kg BA decreased mean expression of these genes, but this effect did not reach 
statistical significance (Figure 3-13B). However, when the effects of BA treatments on all 
aortic M1 genes were analyzed there was a significant effect of the drug on overall M1 
gene expression compared to the HFHC diet alone (P < 0.001) (Figure 3-13B). M2 gene 
expression showed that liver Cd163 expression was significantly lower in HFHC-fed 
mice compared to both the chow and 30 mg/kg BA groups. Expression of M2 genes Arg1 
and Il10 were not different among groups in aorta and liver (Figure 3.14-A). 
Additionally, Adgre1 expression, an estimation of total macrophage content, was 
increased in the liver and aorta of HFHC-fed mice and was not further affected by BA 
treatment (Figure 3-14A). 
Chronic inflammation was assessed by measuring plasma Serum amyloid-A (SAA) 
levels. This liver derived acute-phase protein is rapidly increased during exposure to 
inflammatory stimuli and is also mildly elevated under conditions of low-grade chronic 
inflammation (201, 202). After 12 weeks on diet, the change in plasma SAA 
concentration from baseline was significantly greater in mice fed HFHC when compared 
to mice fed chow (increase of 52% and 13%, respectively). Mice fed the HFHC diet also 
had a significantly greater change in SAA concentrations compared to mice treated with 
30 mg/kg BA (decrease of 19%) (Figure 3-15). 
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Figure 3-9: Effects of BA on glycemia. 
Fasting blood glucose (A) (n=24) and plasma insulin (B) (n=12) sampled every 4 weeks. 
Data are means ± SEM, different letters indicate statistical differences of whole curves by 
two-way ANOVA P < 0.05 
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Figure 3-10: Effects of BA on glucose homeostasis. 
Glucose tolerance test (GTT) (A) and incremental-GTT (iGTT) (B) with area under the 
curve (AUC, inset) (n=12-15). Insulin tolerance test (ITT) (C) and iITT (D) with AUC 
(inset) (n=19-20). Data are means ± SEM, different letters indicate statistical difference 
by one-way ANOVA, P < 0.05. 
 
77 
 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11: Effects of BA on hepatic inflammatory signaling pathways. 
Representative immunoblots of biological replicates for mitogen-activated protein kinase 
(MAPK) and nuclear factor-κB (NF-κB) pathway signaling (A) and quantitations by 
densitometry shown below (B) (n=7-8). Data are means ± SEM, different letters indicate 
statistical differences by one-way ANOVA, P <0.05. 
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Figure 3-12: Effects of BA on aortic inflammatory signaling pathways. 
Representative immunoblots of biological replicates for mitogen-activated protein kinase 
(MAPK) and nuclear factor-κB (NF-κB) pathway signaling (A) and quantitations by 
densitometry shown below (B) (n=5-8). Data are means ± SEM, different letters indicate 
statistical differences by one-way ANOVA, P <0.05. 
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Figure 3-13: Effects of BA on M1 inflammatory gene expression. 
Hepatic M1 gene expression (n=11-12) (A). Full-length aortic M1 gene expression (n=5-
8) (B). Data are means ± SEM, different letters indicated statistically significant 
differences by one-way ANOVA, P < 0.05. 
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Figure 3-14: Effects of BA on M2 gene expression. 
Hepatic M2 gene expression arginase 1 (Arg1) and cluster of differentiation 163 (Cd163) 
(n=11-12) (A). Full-length aortic M2 gene expression Arg1, Interleukin 10 (Il10), and 
Cd163 (n=5-8) (B).  (C) Hepatic and aortic adhesion G protein-coupled receptor E1 
(Adgre1) (macrophage) gene expression (n=6-12). Data are means ± SEM, different 
letters indicated statistically significant differences by one-way ANOVA, P < 0.05. 
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Figure 3-15: Effects of BA on chronic inflammation. 
Percent change in plasma concentration of serum amyloid-A (SAA) from baseline to 12 
weeks on diet (n=10-16). Data are means ± SEM, different letters indicated statistically 
significant differences by one-way ANOVA, P < 0.05.  
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3.8 Bempedoic acid prevents atherosclerotic lesion 
development 
The aortic sinus was sectioned for histological examination of atherosclerotic lesion 
development and morphology. Lesion analysis of H&E or ORO stained sections of the 
aortic sinus revealed the development of small fatty streaks in chow-fed mice, whereas 
the lesions in HFHC-fed mice were significantly larger by 16-fold (Figure 3-16). 
Compared with HFHC-fed mice, treatment with 30 mg/kg BA robustly attenuated lesion 
size (-47%) as measured by lesion area stained with ORO (Figure 3-16). Lipid analysis of 
whole aortae revealed that TC and CE increased significantly in mice fed the HFHC diet, 
as compared to chow-fed mice, and CE was decreased significantly by treatment with 10 
and 30 mg/kg BA.  There was a trend to increased aortic FC and TG with the HFHC-diet 
and a trend to lower FC and TG values in mice treated with BA at 10 and 30 mg/kg 
(Figure 3-17). Lesion morphology was further analyzed by immunohistochemistry (IHC) 
using macrophage and smooth muscle cell-specific antibodies (CD68 and α-actin, 
respectively) and by Picrosirius Red staining for collagen content. Chow-fed mice were 
not included in further lesion analysis due to their small lesion size (Figure 3-16). In 30 
mg/kg BA-treated mice, macrophage content as a percent of lesion area was significantly 
greater than in lesions from HFHC-fed mice, while percent smooth muscle α-actin was 
nonsignificantly lower (Figure 3-18). Total collagen content was unchanged between the 
HFHC and 30 mg/kg groups. Levels of lesion apoptosis, measured by percent of 
activated caspase-3 positive nuclei, were significantly lower with 30 mg/kg BA treatment 
compared to mice fed HFHC alone (Figure 3-19). Collectively, this suggests that in 
addition to smaller lesion size, BA-treated mice have more macrophages, fewer SMCs, 
and fewer apoptotic cells per lesion, consistent with earlier stage lesions. Collectively, 
this implies that BA suppresses the development of atherosclerosis in this model. 
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Figure 3-16: Effects of BA on atherosclerotic lesion development. 
Representative images of H&E or ORO stained aortic sinus sections (A). Quantitation of 
lesion area from ORO images (B) (n=10-13). Data are means ± SEM, different letters 
indicate statistical differences by one-way ANOVA, P <0.05. 
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Figure 3-17: Effects of BA on aortic lipid accumulation. 
Aortic free cholesterol (FC), cholesteryl ester (CE), total cholesterol (TC), and 
triacylglycerol (TG) content (n=11-12). Data are means ± SEM, different letters indicate 
statistical differences by one-way ANOVA, P <0.05. 
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Figure 3-18: Effects of BA on atherosclerotic lesion morphology. 
Representative immunohistochemistry stains for CD68, smooth muscle (SM) α-actin and 
Picrosirius Red (A) with quantitation shown below (B) (n=8-13). Chow mice were not 
included in the analysis due to very small lesion size (see Figure 3-16). Data are means ± 
SEM, different letters indicate statistical differences by unpaired two-tailed t test, P-value 
shown on graph. 
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Figure 3-19: Effects of BA on atherosclerotic lesion apoptosis. 
Representative immunohistochemistry stains of cleaved caspase-3 with quantitation of 
proportion of positively stained nuclei shown on right (n=4-5). Chow mice were not 
included in the analysis due to very small lesion size (see Figure 3-16). Data are means ± 
SEM, different letters indicate statistical differences by unpaired two-tailed t test, P-value 
shown on graph. 
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Chapter 4  
4 Discussion 
CVD risk management has improved tremendously over the past few decades. However, 
CVD continues to be a major cause of death in developed countries, driven in part by the 
rapidly increasing prevalence of the metabolic syndrome and Type 2 Diabetes mellitus.  
Strong evidence from large-scale clinical trials support the notion that lowering LDL-C 
reduces CVD risk. Statins have shown proven efficacy in lowering LDL-C and 
preventing CVD events but despite this, many at-risk patients are unable to reach their 
target LDL-C levels leaving a large group of individuals with significant residual risk. As 
a result, novel therapeutic options are needed to treat cardiometabolic risk factors. 
One significant barrier to managing lipid levels is the often overlooked condition referred 
to as statin intolerance. This has typically lacked a consensus definition and the reported 
prevalence rates can range from 7-29% (203). However, it appears to be gaining 
increasing attention from the medical community. Statin intolerance can be loosely 
defined as when a patient is unable to take a statin due to any number of side effects, thus 
preventing them from achieving their target LDL-C goal (204, 205). Of course, this is a 
major cause for concern due to the increased CVD risk seen with statin noncompliance 
and failure to reach target LDL-C goals (206, 207). Side effects most commonly include 
discomfort from the myopathy-associated muscle pain, along with a small risk for new 
onset of Type 2 Diabetes or a rise in liver function enzymes (205). While these don’t 
negate the CVD benefit seen with statins, it still has a great impact on patient quality of 
life and can reduce compliance.  
Mechanistically, it is thought that the muscle side effects of statins are a result of the drug 
acting directly on muscle tissue (208). Within the skeletal muscle, myocyte dysfunction 
and damage has been suggested to be caused by myocyte HMG-CoA reductase inhibition 
and the resulting lowering of myocyte cholesterol synthesis (209) or off-target effects 
within muscle tissues by statins themselves (210). This myocyte damage can present as 
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muscle pain and myopathy, and perhaps even reduce glucose utilization by muscle, 
increasing blood glucose levels and Type 2 Diabetes risk. 
Bempedoic acid (BA, also known as ETC-1002) is in clinical development for the 
treatment of hypercholesterolemia in patients at a high risk for CVD (details of BA, 
including mechanism of action, are reviewed in section 1.7.6.1). In up to phase IIb 
clinical trials, BA has consistently demonstrated LDL-C lowering of up to 30% as 
monotherapy (171), 50% as an add-on to ezetimibe therapy (174), and 24% as an add-on 
to statin therapy (175). Whether or not this translates into protection from CVD is not 
known. 
The current study was undertaken to address the question of whether or not BA could 
prevent the development of atherosclerosis in Ldlr-/- mice fed a HFHC diet, along with 
other components of the metabolic syndrome such as obesity, dyslipidemia, insulin 
resistance, and chronic inflammation. Mice were randomized to receive a chow diet, a 
HFHC diet, or BA added to the HFHC diet at the doses of 3, 10, or 30 mg/kg. In most 
cases, the metabolic abnormalities assessed were reduced with the dose of 30 mg/kg BA 
over a 12-week period. For example, when compared to mice fed the HFHC diet alone, 
mice treated with 30 mg/kg BA showed reduced body weight and adiposity, reduced 
lipids in the plasma, liver, and aorta, improved glycemia, reduced chronic inflammation, 
and reduced atherosclerotic burden. This effect was often mirrored in mice receiving 10 
mg/kg BA for several, but not all parameters measured. Mice receiving the lowest dose of 
3 mg/kg showed little difference compared to mice receiving HFHC alone for almost all 
the parameters measured. One exception was plasma TG concentration where 3 mg/kg 
BA significantly lowered plasma TG compared to HFHC, with similar efficacy seen with 
the higher two doses of BA. BA at 30 mg/kg was effective in preventing atherosclerosis 
in Ldlr-/- mice fed a HFHC diet. 
4.1 Interpretation and evaluation of results 
4.1.1 Hyperlipidemia and tissue lipid accumulation  
In terms of lipid-based parameters, mice responded as expected to receiving the HFHC 
diet for 12 weeks. Using the Ldlr-/- mouse model in combination with the HFHC diet is a 
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very reliable and robust model of lipid-induced atherosclerosis. The large increase in 
dyslipidemia and atherosclerotic lesion size seen in the HFHC-fed mice attest to this. 
Other lipid-related parameters also demonstrate this, as hepatic and aortic lipids, along 
with adiposity and total body weight, are greatly elevated in mice when comparing 
HFHC feeding to chow. The sheer magnitude of effect size exemplifies the strength of 
this model for studying hyperlipidemia and other components of the metabolic syndrome 
and atherosclerosis.  
Overall, BA showed robust efficacy when it came to preventing the hyperlipidemia and 
tissue lipid accumulation induced by the HFHC diet. Plasma cholesterol and TGs were 
increased several fold in HFHC-fed mice compared to chow. Separation of plasma 
lipoproteins by FPLC analysis revealed that this took place in the VLDL, IDL, and LDL 
cholesterol fractions along with the VLDL TG fractions. 30 mg/kg BA attenuated 
hypercholesterolemia primarily in the VLDL and possibly IDL fractions. 10 mg/kg BA 
also significantly reduced plasma cholesterol, which appeared to take place in the VLDL 
fraction but not to a great enough extent to reach statistical significance. 3 mg/kg did not 
significantly lower plasma cholesterol concentrations compared to HFHC, as was the 
case with most parameters measured. However, it was very interesting to observe that all 
three doses of BA did elicit a statistically significant reduction in plasma TG. This was 
unusual in that it was one of the only parameters for which the 3 mg/kg BA had a 
statistically significant effect compared to the HFHC diet. FPLC analysis showed that 
plasma TG reduction took place in the VLDL fractions, as most plasma TG is found here 
in fasted mice. Although not measured directly, reductions in VLDL cholesterol and TG 
by BA were likely a result of reduced hepatic lipoprotein production. 
4.1.2 Glucose homeostasis 
Other parameters showed a moderate but still significant response to the HFHC diet in 
comparison to chow, although not to the same extent as observed with the lipid 
measurements. Glucose homeostasis was generally worsened with HFHC feeding, as 
shown by increased fasting glucose and insulin, GTTs, and ITTs. When data from the 
tolerance tests were normalized to baseline glucose value, there was still a significant 
difference in glucose sensitivity but there was no significant effect on insulin sensitivity. 
98 
 
This can be interpreted a few different ways. Two important factors that need to be 
considered when interpreting the data are the baseline differences in both body weight 
and blood glucose. Differences in body weight will influence the dose of glucose or 
insulin received. Additionally, increased weight is likely due to increased adiposity while 
glucose disposal is primarily done by lean tissues, such as muscle, brain, and liver (211). 
In the current study, mice fed the HFHC diet received far greater doses of glucose and 
insulin due to their increased body weight. It is therefore possible that glucose tolerance 
was similar between groups and the perceived glucose intolerance in the HFHC-fed mice 
is the result of a larger dose of glucose. Alternatively, it has been suggested that mice 
should receive glucose based on the weight of their lean tissue, not total body weight, if 
such information is available (212). This can be determined by μCT scanning. Fixed 
glucose dosing is also a possibility and has been demonstrated in chow versus high fat 
fed mice (213). Additionally, baseline glucose values were not the same across the 
treatment arms of the study. Therefore, comparisons of the absolute GTT and ITT data 
would not be appropriate and data should be analyzed as glucose normalized to baseline 
or baseline-subtracted glucose (211), as shown in Figure 3-10B and 3-10D. 
When looking at fasting glucose values taken over the course of the study, an interesting 
trend becomes apparent. Statistical analysis of the time course plots showed that mice in 
the chow and 30 mg/kg BA groups had significantly lower fasting glucose values than the 
HFHC and 3 and 10 mg/kg BA groups. It is stated in the results section that this is an 
attenuation of hyperglycemia, but closer inspection of the graphs suggests that the HFHC 
and lower dose BA groups had no change in glycemia while the chow and high dose BA 
groups displayed a reduction in glycemia. A likely explanation is that at baseline, mouse 
glucose values were slightly inflated due to a stress response from the tail bleed 
procedure. In fact, it is known that mice will increase glucose production under 
conditions of stress, likely through an increase in levels of catecholamines and cortisol 
(214, 215). As the study progressed, mice became more acclimatized to the glucose 
monitoring procedure so that by week 12, normoglycemic mice (chow and 30 mg/kg BA) 
showed a reduction while hyperglycemic mice (HFHC and 3 and 10 mg/kg BA) show no 
change in fasting blood glucose concentrations. If this scenario is true, then it would be 
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valid to suggest that chow and 30 mg/kg BA groups are normoglycemic relative to the 
other three groups which display hyperglycemia, as stated in section 3.6.  
4.1.3 Metabolic measures 
A number of metabolic measurements were taken including fatty acid β-oxidation, fatty 
acid synthesis, and metabolic cage analyses such as oxygen utilization, and carbon 
dioxide production. Fatty acid β-oxidation was measured using radiolabeled [3H]-palmitic 
acid and tracking its conversion to deuterated water (
3
H2O). While most of this process 
takes place in the mitochondria, peroxisomes are another potential site of β-oxidation and 
both organelles contain similar enzymes but with different substrate specificities (216, 
217). Specifically, all very-long-chained fatty acids (24-30 carbons) and some long-chain 
fatty acids (12-22 carbons) undergo β-oxidation exclusively in peroxisomes, most long-
chain fatty acids and all medium-chain (6-12 carbons) and short-chain (<6 carbons) fatty 
acids undergo β-oxidation in the mitochondria (218). Since BA treatment had a large 
peroxisome proliferation effect, peroxisomal β-oxidation could account for much of the 
increased fatty acid β-oxidation of long-chain and very-long chain fatty acids. While the 
relative contribution of mitochondrial and peroxisomal β-oxidation was not determined, 
this could be estimated by performing the β-oxidation assay with or without a CPT1α 
inhibitor (such as etomoxir (219)). During inhibition of mitochondrial β-oxidation, the 
remaining β-oxidation would likely be peroxisomal, although this theory has yet to be 
validated. 
Fatty acid synthesis was analyzed my measuring the incorporation of [1-
14
C]-acetic acid 
into fatty acids. A very important consideration for using this method is the effect of 
radiolabeled substrate dilution within the endogenous cytosolic acetyl-CoA pool (220–
224). Therefore, the assumption is made that acetyl-CoA pool sizes and thus radiolabel 
dilutions are equal between groups. However, the current study employs a specific 
inhibitor of acetyl-CoA synthesis and it is known that BA reduces intracellular acetyl-
CoA concentrations (177), so these results should be interpreted cautiously. An 
alternative approach is to use tritium-labeled water (
3
H2O) as its specific activity should 
be similar between experimental groups (221). However, a major limitation of this 
approach is the very high amounts of radioactivity necessary to perform assays using 
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tritium-labeled water as substrate, especially when studying a large number of subjects 
(221). 
Metabolic cages were used to measure volume of oxygen utilized (VO2) and carbon 
dioxide produced (VCO2). The analysis of murine energy expenditure has long been an 
area of controversy and different means of data analysis can yield very different results 
(225–231). It is common to find literature example of misinterpretations of data or 
unsubstantiated conclusions (231). One of the greatest confounding factors of energy 
metabolism in humans and mice is the role of body mass (225, 226). While it is known 
that energy expenditure increases with body mass, this relationship is certainly not linear. 
In models of diet-induced obesity, increased body mass is driven by increased adiposity. 
While adipose tissue does contribute to energy expenditure, the effect is not as great as 
the contribution from lean tissue.  However, it is very common for investigators to 
normalize energy expenditure to total body mass, thus in a model of diet-induced obesity 
this will give the appearance of diminished energy expenditure in the obese group (225). 
A better way to characterize energy expenditure when body weight differences are 
present is to normalize the data to each mouse's lean body mass, which can be determined 
by μCT or nuclear magnetic resonance imaging. A much more robust method involves 
using analysis of covariance (ANCOVA), where energy expenditure is plotted in relation 
to body weight or lean body weight for each individual mouse. Displaying the data this 
way reveals if differences in energy expenditure are the result of different body weights, 
or if the treatment has an effect compared to the control group (225, 226). Another 
important consideration when doing energy expenditure analysis is that very subtle 
changes in metabolic rates can have a significant effect over a long period of time (229). 
Taking the current study as an example, a small reduction in body weight seen in BA-
treated mice compared to HFHC-fed controls (~ 2 grams) occurred over the course of the 
12-week study. Assuming this is 2 grams of pure fat, this would represent 74 kJ of energy 
(2 x 37 kJ/gram fat) and thus a difference in energy expenditure of ~0.9 kJ per day over 
the 12-week study. Assuming there are no differences in caloric intake between mice fed 
the HFHC diet compared to BA-treated mice, and that an average mouse has an energy 
expenditure of 50-60 kJ/day(231), BA-treated mice only need to expend < 2% more 
energy to display the observed difference in body weight. Needless to say, such a small 
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difference in daily energy expenditure is far less than what indirect calorimetry can 
accurately detect (231). 
4.1.4 Inflammation 
The effects of BA on inflammation were assessed by measuring several markers of 
inflammation in the liver, aorta, and plasma. The HFHC diet induces chronic, metabolic 
inflammation, exacerbated by the addition of cholesterol. This effect is moderate, in 
contrast to the large effect seen in acute inflammation, such as when lipopolysaccharide 
(LPS) is administered to mice (232, 233). Analyses of inflammatory gene expression, 
intracellular signaling pathways, and plasma markers were carried out to try and detect 
the low grade inflammation seen with the HFHC diet and its resolution seen with BA 
treatment. 
The effects of the HFHC diet can be seen on hepatic and aortic inflammatory gene 
expression in comparison to chow fed mice. One set of genes represents an M1 
macrophage phenotype, which is indicative of classically activated, proinflammatory 
macrophages. This is in contrast to M2 genes which represent alternatively activated, 
reparative, anti-inflammatory macrophages. In liver there was a suppressive effect of the 
HFHC diet on M2 gene expression, but not in aortae. Additionally, total macrophages 
content was increased in the aortae and liver of mice fed the HFHC diet compared to 
chow-fed mice, as measured by Emr1 gene expression. Overall, BA attenuated this 
proinflammatory gene expression pattern. This was observed with 30 mg/kg BA-treated 
mice for most hepatic proinflammatory genes measured. Additionally, hepatic Nos2/Arg1 
was reduced in 30 mg/kg BA-treated mice compared to HFHC-fed mice, suggesting that 
the population of macrophages present in the liver displayed more of an M2 phenotype. 
In the aorta, BA at any dose did not significantly lower proinflammatory gene expression 
but trends can be observed in the data for the 10 and 30 mg/kg doses. Collectively, 
comparing expression of all aortic M1 genes between groups fed the HFHC diet +/- BA 
by two-way ANOVA revealed a significant effect of BA compared to HFHC-feeding 
alone (P < 0.0001). The lack of any statistically significant effect in the aorta on any 
individual gene is likely attributable to an insufficient sample size for these relatively low 
abundance mRNAs. Chow-fed mice showed relatively constant aortic M1 gene 
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expression while in HFHC-fed mice, expression was highly variable. The intermediate 
M1 gene expression seen in BA-treated mice was also highly variable. With this high 
standard deviation and a total 5 treatment groups, a much greater sample size would have 
been needed to detect statistically significant effects of BA on aortic inflammation. 
Intracellular inflammatory signaling was also assessed by immunoblotting for 
phosphorylated MAPK and NF-κB pathway proteins. Overall there was a limited effect 
of the diet on the phosphorylation of these proteins, and in many instances there was no 
difference between chow and HFHC-fed mice. This was unexpected since the 
inflammatory gene expression data did show an effect of the HFHC diet. 30 mg/kg BA 
treated mice showed reduced phosphorylation of hepatic ERK and p38 and aortic JNK, 
compared to HFHC fed mice while other MAPK proteins and none of the NF-κB proteins 
showed any differences. A likely explanation is that the chronic low-grade inflammation 
seen with in HFHC fed mice has a very subtle effect on phosphorylation of MAPK and 
NF-κB proteins, below what phosphoprotein immunoblotting could accurately detect. 
This small effect size combined with the small sample size (8 or less) likely explains the 
limited differences seen in inflammatory signaling pathway phosphorylation. 
A third marker of inflammation was performed by measuring plasma concentrations of 
the SAA protein. This acute-phase protein is rapidly secreted by the liver in response to 
inflammatory stimuli. Additionally, it is modestly elevated under conditions of chronic 
inflammation. Unexpectedly, several mice exhibited very large increases in SAA 
concentration (100-fold greater than group mean) independent of treatment group and 
study time point. In these cases, mice consistently exhibited signs of aggression and 
dominance behavior, occasionally having visible wounds. This is not atypical mouse 
behavior, especially among male mice and other investigators have made similar 
observations (234, 235). These mice were excluded and in the remaining mice the change 
in SAA from baseline to week 12 was analyzed. Mice fed chow showed little change in 
SAA concentration while in mice fed the HFHC diet plasma SAA was increased by 
approximately 50%. This was prevented in mice treated with 30 mg/kg BA and their 
SAA concentrations actually showed a slight decrease from baseline. This is likely owing 
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to the known anti-inflammatory properties of BA, as demonstrated by the CRP lowering 
seen in clinical trials. 
4.1.5 Atherosclerosis 
As mentioned in section 4.1.1, the Ldlr-/- mouse is a good model of atherosclerosis due 
to the severity of dyslipidemia that develops in response to the HFHC diet. As expected, 
the HFHC-fed mice developed very large lipid and foam cell-rich lesions within the 
aortic roots, while lesions in chow-fed animals were barely detectable. 30 mg/kg BA 
showed a robust reduction in lesion size compared to HFHC-fed mice an effect which 
was comparable to the degree of plasma cholesterol lowering. Further analyses were 
performed to study lesion composition and morphology. In addition to a reduced lesion 
size, BA treated mice had a higher macrophage content, slightly lower smooth muscle 
cell contents, and a reduced percentage of apoptotic cells, all indicative of a less 
advanced stage lesion. 
4.2 The question of mechanism 
Overall, these findings are consistent with BA inhibiting hepatic ACL and activating 
AMPK. Additionally, BA appeared to stimulate PPARα activation which offers a third 
mechanistic explanation of the results. The current study was not designed to determine a 
specific mechanism(s). However, comparing the data from BA-treated mice with 
literature data may offer insight into the relative contributions of the three potential 
mechanisms. 
4.2.1 Comparison to related drugs and mouse models 
Many previous studies have looked at genetic knockouts, overexpression, or chemical 
inhibition or activation of AMPK, ACL, PPARα, or closely related pathways in mouse 
models of metabolic disease. These studies can be helpful when interpreting the data 
from the current study. 
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4.2.1.1.1 AMPK 
Activation of AMPK under conditions of low intracellular energy results in an 
upregulation of catabolic, ATP-producing pathways and an inhibition of anabolic, ATP-
consuming pathways (See section 1.7.5). Therefore, it is thought to be a promising drug 
target for the treatment of metabolic diseases. Most AMPK activators work via inhibition 
of the mitochondria respiratory chain, thus increasing cellular AMP levels and AMPK 
activation (236). Therefore, these are indirect activators and are not specific for AMPK. 
BA has been shown to activate AMPK without altering adenylate nucleotide levels (177), 
decreasing the likelihood of an AMP-mediated mechanism of AMPK activation. 
Resveratrol and other polyphenols are good examples of indirect AMPK activators that 
have been very well studied. While the mechanisms of polyphenols are complex and 
controversial (237) their cardioprotective potential has been demonstrated in several 
animal models (238–241). For example, the synthetic polyphenol S17834 has been 
shown to activate AMPK while inhibiting diet-induced hepatic steatosis, hyperlipidemia, 
and atherosclerosis in Ldlr-/- mice (240). These effects are thought to involve AMPK-
mediated inhibition of SREBPs (242). Specifically, S17834 was shown to reduce hepatic 
expression of SREBP-2 and its target genes (242). In contrast, BA appeared to increase 
SREBP-2 target gene expression, which may be a feedback effect from cholesterol 
synthesis inhibition. 
While compounds that activate AMPK indirectly have been well studied, direct AMPK 
activators have only been characterized relatively recently. Compound A-769662 was 
developed by Abbott Laboratories and was the first described direct AMPK activator 
(243). It was demonstrated to activate AMPK independently of upstream kinases (244) 
and cellular AMP levels (245) in a manner requiring the β-subunit of AMPK (245, 246). 
Additionally, A-769662 preferentially activated β1-containing complexes over β2 (246). 
In leptin-deficient (ob/ob) mice, a model of diet-induced obesity, A-769662 was effective 
in reducing plasma glucose, body weight, and plasma and liver TG, but displayed poor 
bioavailability (243). Salicylate was also found to bind the same β1-subunit site as A-
769662 and had similar effects (154). Although it has better bioavailability, its effects on 
atherosclerosis are not yet known. Based on this information and the similar metabolic 
105 
 
effects observed with BA, it would be interesting to test if BA has similar AMPK β1-
subunit binding properties. 
Two additional compounds known as 991 (247) (also known as ex229 (248)) and MT 63-
78 (249) have been recently developed and also show preference towards the AMPK β1-
subunit (236). Compound C13 (and its metabolite C2) has been shown to directly target 
α1-containing AMPK complexes (250, 251). Lastly, CNX-012-570 has been shown to 
directly activate γ-containing subunits (252). Collectively, these direct activators have 
only been characterized very recently and several key aspects such as bioavailability and 
toxicology profile have not been described. It is difficult to make comparisons of these 
compounds with BA, until further information on these compounds are published. 
Therefore, while AMPK activation can certainly be observed with BA treatment (177, 
178) the contributing role of AMPK activation in BA’s mechanism of action remains 
undetermined. 
4.2.1.1.2 ACL 
Besides BA, other inhibitors of ACL have been tested but none are currently in clinical 
development. Prior examples of ACL inhibitors include hydroxycitrate, a natural 
inhibitor (253–256), and the synthetic inhibitors BMS-303141 (257–259) and SB-204990 
(260–262). However common issues with these compounds include poor membrane 
permeability and the high doses required to elicit an effect, resulting in off-target effects 
(170, 253, 263). 
Previous studies of in vivo inhibition of ACL have reported very similar effects as seen 
with BA treatment. For example, treatment of rats with hydroxycitrate inhibited hepatic 
cholesterol and fatty acid synthesis (254–256, 264). Treatment of rats with SB-204990 
reduced plasma cholesterol and TG (262) while treatment of high-fat fed mice with 
BMS-303141 reduced plasma lipids, glucose, and body weight gain (259).  
Of particular interest are studies where ACL knockdown was performed specifically in 
the liver. Wang, et al. demonstrated that in leptin receptor-deficient (db/db) mice this 
reduced hepatic levels of acetyl-CoA, malonyl-CoA, lipogenesis, and TG while also 
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improving fasting glucose, and glucose tolerance (165). Interestingly, hepatic gene 
expression analysis revealed a small increase in SREBP-2 expression similar to what was 
seen with BA. However, expression of ACC and FAS were suppressed in the ACL 
deficient mice, in contrast to what was seen with BA in the current study. Additionally, 
ACL deficient mice showed a marked suppression of Ppara and Acox expression (165), 
in contrast to the large induction seen with BA treatment. This is likely owing to the fact 
that in the current study, BA treatment in mice likely inhibited ACL and activating 
PPARα while the study by Wang, et al. looked a hepatic ACL deficiency alone (165). A 
follow up study examined hepatic ACL knockdown in wild type mice fed either a low- or 
high-fat diet (166). Again, ACL knockdown reduced hepatic acetyl-CoA, malonyl-CoA 
and plasma TG on both diets, and while hepatic VLDL TG secretion was also reduced, 
hepatic TG was actually increased (166). The latter result is difficult to reconcile with all 
the other findings, and it is important to note that different diets and mouse models can 
sometimes produce very different effects. Overall, however, these examples are mostly 
consistent with the notion that the effects of BA in the current study are largely mediated 
by hepatic ACL inhibition. 
4.2.1.1.3 PPARα 
Peroxisome proliferator-activated receptor α (PPARα) is a transcriptional regulator of 
genes involved in lipid and lipoprotein metabolism, with a significant effect on regulating 
β-oxidation (265). It is the target of most fibrates, a class of drugs in clinical use as an 
add-on therapy for hyperlipidemia (265, 266). PPARα has been best studied for its role in 
the liver but it is also highly expressed in heart, kidney, and muscle (267–269). In the 
current study, there is a clear peroxisome proliferation effect of BA on murine liver, 
possible due to PPARα activation.  
The effects of fibrates in mouse models of cardiovascular disease have been mixed. The 
fibrate ciprofibrate was shown to increase plasma cholesterol and atherosclerosis in 
Apoe-/- mice (270) and Ldlr-/- mice (271). Fenofibrate was also shown to increase 
plasma cholesterol but have no effect on atherosclerosis in Apoe-/- mice (272, 273) while 
conversely reducing plasma lipids and atherosclerosis in Ldlr-/- mice (274). Gemfibrozil 
decreased cholesterol and atherosclerosis in Apoe-/- mice (275, 276). Bezafibrate 
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decreased cholesterol and atherosclerosis in Ldlr-/- mice (277). Clearly there is difficulty 
in interpreting this data. However, if one looks at only the studies in Ldlr-/- mice where 
fenofibrate and bezafibrate were shown to reduce atherosclerosis, the data is very similar 
to the results of BA treatment in the current study. For example, similar to BA, fibrate 
treatment reduced body weight, fat pad mass, plasma cholesterol and TG, and 
atherosclerosis, while also increasing Aco gene expression (274, 277). 
An important thing to note about PPARα agonists is that rodent models are highly 
sensitive to peroxisome proliferators. Even under short exposure to fibrates, rodents will 
display large increases in liver weight due to both hyperplasia and hypertrophy (278). 
This is precisely what was observed with BA treatment. Furthermore, under chronic 
exposure of peroxisome proliferators rodents will display an increased incidence of 
hepatocellular carcinoma (278, 279). It should be noted however, that this effect has not 
been observed in humans or primates and for several decades fibrates have been in 
clinical use for hypertriglyceridemia (279–281). Additionally, BA has successfully 
completed long-term carcinogenicity and toxicology studies in rats and mice as required 
by the Food and Drug Administration (282, 283). 
In the current study, the large increase in fatty acid synthase (Fasn) gene expression seen 
with BA treatment could further play a role in PPARα activation. The Semenkovich lab 
previously demonstrated that knockout of Fasn in the liver of mice unexpectedly resulted 
in fasting hypoglycemia, hepatic steatosis, and other phenotypes similar to that seen in 
Ppara knockout mice (284). This suggested that FAS synthesizes an endogenous ligand 
for PPARα, which the group showed in a later study (285). These studies demonstrated a 
greater role for FAS beyond the storage of excess nutrients as fat. It appears that FAS can 
work though signaling mechanisms to impact liver physiology (286). Therefore, it is 
entirely possible that the large increase in Fasn expression seen with BA treatment could 
be at least in part responsible for the increased PPARα activation. 
In summary, the metabolic benefits seen with BA appear similar to some (but not all) 
findings from studies of fibrates in mice. The strongest evidences for the involvement of 
PPARα in the mechanism of action of BA are both the large increase in hepatic Aco gene 
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expression and the increase in total liver mass. Authors of a previous study made very 
similar observations (including a lack of increased hepatic Ppara expression), leading 
them to suggest a mechanism that involves PPARα activation (287). Additionally, 
increase fatty acid synthase activity (although not measured directly) could contribute to 
this PPARα effect. 
4.2.2 Comparison to clinical data    
It is difficult to fully know the clinical implications of a drug based solely on data from 
animal models. The discussion of PPARα and fibrates in the previous section exemplifies 
this as studies in rodents inconsistently demonstrate a benefit with fibrates, while also 
revealing side effects that appear to be clinically irrelevant. The current study 
demonstrated that in Ldlr-/- mice fed a HFHC diet, BA can lower TG and cholesterol in 
the plasma, liver, and aorta, increase hepatic lipid metabolism, improve glucose 
homeostasis, lower markers of inflammation, and reduce atherosclerosis. These data 
suggest a mechanism of action that very likely involves the inhibition of ACL, with a 
possible contribution of AMPK activation, and certain involvement of PPARα activation 
(based on increased liver size and Aco expression). In comparison, human trials with BA 
have demonstrated robust efficacy in lowering LDL-C, non-HDL-C, apoB, and hsCRP 
with limited effects on plasma TG, glycemia, blood pressure, and body weight. The lack 
of any clinically significant effects on plasma TG in particular suggests that the human 
mechanism does not involve PPARα activation. Collectively, the published literature on 
the use of BA in clinical trials strongly suggests that in humans, BA’s primary 
mechanism of action in humans is the inhibition of hepatic ACL, a limited but 
undetermined effect of AMPK activation, and no effect on PPARα activation. 
4.3 Conclusions 
The results from this study demonstrate the clear efficacy of BA in preventing 
atherosclerosis and other aspects of the metabolic syndrome in Ldlr-/- mice fed a HFHC 
diet. Future studies should further expand both the current understanding of BA’s 
mechanism of action while also determining if there any side effects or additional 
benefits of chronic BA treatment. It remains to be determined what the contributions are 
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of ACL, AMPK, and PPARα in BA’s metabolic effects. This can be explored using 
knockout mice where each of these proteins are deleted in a whole-body, or preferably, a 
liver-specific manner. Additionally, to determine the effects of BA on inflammation, 
better in vivo inflammatory models could be utilized. As discussed already, using mice 
receiving a large inflammatory stimulus would be superior to the chronic inflammation 
seen in obesity for testing BA’s potentially anti-inflammatory effects. One additional 
question that remains to be answered is whether or not BA has any lipid-independent 
effects. Utilizing the inflammatory model just mentioned with acute BA treatment could 
help answer this question, especially if any effects of BA on inflammation can be 
detected prior to any changes in hepatic or plasma lipid levels. 
In addition to further preclinical research, there remains much work to be done in human 
clinical trials which are already well underway. Moving forward, it will be very 
interesting to see how BA performs in future and ongoing clinical trials. Currently, 
patient enrollment has begun for two additional trials. First, a Phase 2b trail will look at 
the effects of BA when added to a high-dose (80 mg) of atorvastatin (NCT02659397). 
And next, a Phase 3 trial will look at the long-term safety and tolerability of BA in high-
risk patients with hyperlipidemia and high CVD risk (NCT02666664). Results from these 
studies are eagerly anticipated.  
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